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6ABSTRACT
The behavioural effects of many drugs of abuse increase gradually when they are
administered repeatedly, i.e. their behavioural effects are sensitized. Behavioural
sensitization can be maintained for months after repeated administration of morphine
and other opioids, and it has been associated with drug dependence. The mechanisms
involved in the sensitization are not fully clarified. There is evidence of the
involvement of cerebral dopaminergic systems in the sensitization to morphine, but
participation of neural systems other than the dopaminergic system may also be
required in the expression of sensitization. The present series of studies was conducted
to study the involvement of cerebral dopaminergic and noradrenergic systems in the
behavioural sensitization to morphine in mice.
Morphine was given repeatedly to mice for 5 days. After 1, 3 or 5 days' withdrawal, an
acute morphine challenge dose was given. The morphine withdrawal and challenge-
induced changes in striatal dopamine (DA) metabolism, and in cerebral noradrenaline
(NA) metabolism were measured post mortem in tissue samples by high-performance
liquid chromatography with electrochemical detection; the morphine-induced changes
of locomotor activity were measured as well. Furthermore, the effects of an α2-
adrenoceptor antagonist, idazoxan, on the morphine-induced changes in striatal DA
and cerebral NA metabolism, as well as in locomotor activity, were studied in mice
withdrawn for 3 days from the repeated morphine treatment.
Acute morphine increased striatal DA turnover and release to a greater extent in mice
withdrawn for 3 or 5 days from the repeated morphine treatment than in control mice,
while mice were tolerant to the cerebral NA turnover and release increasing effect of
acute morphine when withdrawn for 1 or 3 days. At 1-day withdrawal mice were
tolerant to the acute morphine-induced locomotor hyperactivity, at 3-day withdrawal
the activity was increased similarly as in control mice, but at 5-day withdrawal mice
were sensitized to the acute morphine-induced locomotor hyperactivity. Pretreatment
7with idazoxan did not potentiate the acute morphine-induced increase of striatal DA
turnover and release in mice withdrawn for 3 days from the repeated morphine
treatment, but abolished the tolerance towards the acute morphine-induced increase of
cerebral NA turnover and release in these mice. Idazoxan pretreatment did not alter the
locomotor hyperactivity induced by acute morphine in control mice but clearly
potentiated it in the morphine-withdrawn mice.
The temporal coupling of morphine-induced changes in striatal DA and cerebral NA
metabolism, and in locomotor hyperactivity suggests that the morphine-induced
locomotor sensitization is expressed in mice only when they are sensitized to the
striatal DA turnover and release increasing effect of acute morphine, and when acute
morphine increases cerebral NA turnover and release to the same extent as in naive
mice. Thus, the present results emphasize the role of striatal dopaminergic, as well as
cerebral noradrenergic systems, in the expression of behavioural sensitization to
morphine in mice.
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9ABBREVIATIONS
AH aldehyde dehydrogenase
ANOVA analysis of variance
ATP adenosine triphosphate
cDNA complementary deoxyribonucleic acid
COMT catechol-O-methyltransferase
DA dopamine
L-DOPA L-dihydroxyphenylalanine
DOPAC 3,4-dihydroxyphenylacetic acid
DOPEG 3,4-dihydroxyphenylethyleneglycol
GABA gamma-aminobutyric acid
HVA homovanillic acid
5-HT 5-hydroxytryptamine
i.c.v. intracerebroventricular
i.p. intraperitoneal
MAO monoamine oxidase
MOPEG 3-methoxy-4-hydroxyphenylethyleneglycol
αMT α-methyl-p-tyrosine
3-MT 3-methoxytyramine
NA noradrenaline
s.c. subcutaneous
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1. INTRODUCTION
Since 1954 when Marthe Vogt demonstrated that noradrenaline (NA) is non-uniformly
distributed in the mammalian brain and showed that morphine administration lowers
NA concentration in the hypothalamus of cats, the effects of morphine and other
opioids on peripheral, as well as on central catecholamines, have been studied
extensively.
Withdrawal from chronic use of morphine and other opioids is characterized by
specific signs. Clonidine, an α2-adrenoceptor agonist, has been successfully used in the
treatment of the opioid withdrawal syndrome (Cooper et al. 1996), indicating that the
noradrenergic systems play an important role in the withdrawal reaction. In addition to
cerebral NA, morphine and other opioids are known to alter cerebral dopamine (DA)
transmission. It has been suggested that the effects of morphine and other dependence
producing drugs on the mesolimbic dopaminergic transmission are crucial in the
development of dependence on these drugs (Wise and Bozarth 1987; Robinson and
Berridge 1993; Feldman et al. 1997).
Morphine and other opioids alter the locomotor activity of experimental animals.
When morphine is administered repeatedly to rats, tolerance develops towards the
locomotor activity decreasing effect of acute morphine, and the locomotor activity
increasing effect of morphine is increased (Vasko and Domino 1978; Brady and
Holtzman 1981; Kalivas and Duffy 1987; Rauhala et al. 1995). There are studies
suggesting that the phenomenon, i.e. behavioural sensitization, is evident in mice as
well (Fernandes et al. 1977; Gwynn and Domino 1984; Kuribara and Tadokoro 1989;
Kuribara 1995, 1997). In addition to the locomotor activity increasing effects of
morphine and other dependence producing drugs, their reinforcing effects are
sensitized after repeated administration. This has been associated with the
development of dependence on these drugs (Koob and Bloom 1988; Robinson and
Berridge 1993; Feldman et al. 1997). As the locomotor activity increasing effects of
11
morphine and of other dependence producing drugs have been suggested to be
mediated at least partially by the same cerebral mechanisms as their reinforcing
effects, alterations in the locomotor activity can be used as a tool when elucidating the
reinforcing properties of these drugs (Wise and Bozarth 1987; Robinson and Berridge
1993; Spanagel et al. 1996).
The role of the cerebral dopaminergic systems in the behavioural sensitization to
morphine has been studied extensively in rats. Striatal DA is involved in the
progressive increase of stereotypies induced by repeated administration of opioids
(Ahtee 1974). Although it has been suggested that increased mesolimbic dopaminergic
activity may be associated with the behavioural sensitization to morphine in rats (Wise
and Bozarth 1987; Acquas et al. 1991; Spanagel et al. 1993) the role of cerebral
dopaminergic systems in the behavioural sensitization in mice has not been similarly
studied. Furthermore, it is possible that neurotransmitters other than DA are associated
with the initiation or expression of sensitization, even in rats (Kalivas and Stewart
1991) and that there are sensitization-related changes in other neurotransmitter systems
as well (Robinson and Berridge 1993). In mice, the cerebral noradrenergic systems, in
addition to the dopaminergic systems, have often been found to be involved in the
morphine-induced changes in locomotor activity (Estler 1973; Kempf et al. 1976;
Michaluk et al. 1991). Although the role of cerebral noradrenergic systems in the
behavioural sensitization to morphine is still unclear, it has been suggested that in rats
NA may have at least a regulatory role in the expression of DA-induced locomotor
behaviour (Dickinson et al. 1988). Furthermore, there is evidence on the regulatory
role of cerebral noradrenergic systems in the locomotor hyperactivity induced by
amphetamine in rats (Ögren et al. 1983; Mohammed et al. 1986; Darracq et al. 1998)
and it has been suggested that psychomotor stimulant-induced increase of NA release
may be sufficient in mediating the eliciting properties of these drugs (Tessel 1990).
The present series of studies was carried out to investigate the roles of cerebral
dopaminergic and noradrenergic systems in the morphine-induced behavioural
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sensitization in mice. This was done by investigating the temporal coupling of the
effects of repeated morphine administration and withdrawal and of acute morphine
challenge on striatal DA and cerebral NA metabolism, as well as on locomotor
activity. Furthermore, as withdrawal from repeated morphine treatment may alter the
binding of striatal DA D1- and D2-receptors (Carlson and Cooper 1985; Martin and
Takemori 1986; Bhargava and Gulati 1990) and thus contribute to the sensitization, the
effects of repeated morphine treatment and withdrawal on striatal D1- and D2-receptors
were studied. The role of the cerebral noradrenergic systems in the locomotor
sensitization was clarified in more detail by elucidating the effects of blockade of NA
release inhibiting α2-adrenoceptors by idazoxan on morphine-induced changes in
striatal DA and cerebral NA metabolism, as well as in locomotor activity.
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2. REVIEW OF THE LITERATURE
2.1. Morphine and opioid receptors
Substances with morphine-like effects, i.e. the opioids, being unsurpassed in reducing
pain, have been used for analgesia and other purposes for centuries and are still widely
used in all branches of medicine despite their undesirable side effects and their
potential for addiction. Since 1806, when the active ingredient of opium, morphine,
was isolated, more than 25 other alkaloids have been purified from opium. In addition,
numerous synthetic derivatives with structures related or unrelated to morphine have
been synthetised to alleviate pain. The structure of morphine (Fig. 2-1) was not
identified until 1925. In addition to their analgesic effects the opioids act on the central
nervous system to produce hypnotic effects and drowsiness, mood changes and mental
clouding. On the gastrointestinal tract opioids produce decreased gastric motility and
reduce gastric and intestinal secretion, causing constipation. Medicinal uses of opium
alkaloids and related compounds are numerous but most often they have been used for
diarrhoea and severe pain.
Fig. 2-1. Chemical structure of morphine.
Characteristic of the effects of opioids is rapid development of tolerance which may
induce an addict to take massive doses, lethal to a non-addicted person. Subjects
tolerant to opioids must increase their dosage in order to avoid the specific opioid
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withdrawal syndrome, characterised by withdrawal signs: loss of weight and appetite,
aggresiveness, diarrhoea and convulsions. A powerful sense of euphoria is another
effect of opioids, which contributes to compulsive drug abuse. Experimental animals
are prone to self-administration of opioids as well.   
Morphine is readily absorbed through most mucous membranes and is administered
most commonly by subcutaneous injection. Despite the fact that morphine has its
greatest effects in the central nervous system, only small quantities reach the brain.
The kidney is the principal route of excretion. Most of the administered drug is found
in the urine within 24 hours of administration. Some of the morphine is excreted
unchanged but the largest portion is combined with glucuronic acid to form morphine-
3- and morphine-6-glucuronide, and to a lesser extent morphine-3-sulphate and
normorphine. Morphine-6-glucuronide is an active metabolite. Although inactive,
morphine-3-glucuronide and morphine-3-sulphate bind to opioid µ-receptors to some
extent (Chen et al. 1991). However, in mice, the main metabolite of morphine,
morphine-3-glucuronide, does not bind to opioid receptors or alter the locomotor
activity (Smith et al. 1990; Mφrland et al. 1994).
Specific receptors for morphine-like drugs were first suggested in 1967, and in 1973
their stereospecific binding sites were identified. Opioid receptors are classified into µ-
, δ- and κ-receptors. Previously other binding sites were proposed to be opioid
receptors but currently they are categorised as modulatory binding sites for other
receptors.
After the discovery of opioid receptors, endogenous ligands for these receptors were
characterised. The endogenous opioid peptides, ß-endorphin, enkephalins and
dynorphins, are derived from three distinct precursor molecules, proopiomelanocortin,
proenkephalin and prodynorphin. Cell-specific cleavage results in different products
from identical precursor molecules in different cell types (Feldman et al. 1997).
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Opioid receptors have been localised in both the brain and spinal cord. In the brain the
highest densities of µ-receptors are found in the thalamus and the periaqueductal grey;
the δ-receptors are found in the basal ganglia and the κ-receptors in the cerebral cortex
and amygdala (Mansour and Watson 1993; Reisine and Pasternak 1996; Feldman et al.
1997).
The µ-receptor has high affinity for endorphins and morphine. The localisation of µ-
receptors suggests their participation in analgesia, positive reinforcement, sedation,
sensorimotor integration, as well as in cardiovascular and respiratory depression
(Reisine and Pasternak 1996; Feldman et al. 1997). Morphine and enkephalins label µ-
binding sites with varying affinity. The site with high affinity for both morphine and
enkephalins has been nominated µ1-receptor. The localisation of µ1-receptors suggests
that they have an important role in mediating analgesia. µ2-Receptors have a slightly
lower affinity for morphine and enkephalins. Respiratory depression and inhibition of
gastrointestinal transit are thought to be mediated by µ2-receptors (Reisine and
Pasternak 1996; Feldman et al. 1997).
The δ-receptor binds enkephalins and its cerebral distribution is similar to that of µ-
receptors. The possible physiological role for δ-receptor is in analgesia, olfaction,
motor integration and cognitive functions. Based on receptor labelling studies, two
subclasses (δ1 and δ2) have been proposed (Reisine and Pasternak 1996; Feldman et al.
1997). 
The κ-receptor is the binding site for dynorphins. κ-Receptor may participate in the
regulation of feeding behaviour, temperature control, gut motility, analgesia and
neuroendocrine function. In rat brain, κ-receptors have a distinct distribution pattern
compared with µ- and δ-receptors. Several κ-receptor subtypes exist. In addition to κ1
and κ2, binding studies have proposed κ3 and κ4 subtypes although pharmacological
and physiological evidence for these is lacking (Reisine and Pasternak 1996; Feldman
et al. 1997).
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Opioid receptors are proteins embedded in the cell membrane to which morphine and
other opioid agonists bind to initiate their pharmacological effects. All three opioid
receptor subtypes have a 7-transmembrane domain structure. cDNAs encoding each
class of opioid receptors have been isolated and the predicted amino acid sequences of
the receptor proteins have been obtained. All the cloned opioid receptors are strikingly
similar to each other both in their molecular weight and amino acid sequence. The
highest homology between the receptor proteins is found in the putative
transmembrane domains, in the intracellular loops and in the portion of C-terminal tail
adjacent to the seventh transmembrane domain (Reisine and Pasternak 1996; Feldman
et al. 1997). Opioid receptors are coupled to the inhibition of adenylyl cyclase activity
via pertussis toxin sensitive G-proteins. Activation of opioid receptors reduces Ca2+-
entry and increases K+-conductance (North 1993; Feldman et al. 1997). 
2.2. Catecholaminergic pathways in the brain
2.2.1. Dopaminergic pathways
Dopaminergic neurons can be divided into 3 major classes depending on the length of
the dopaminergic tract. The long projections consist of three separate tracts:
nigrostriatal, mesolimbic and mesocortical projections.
 
The neuronal cell group A9, largely corresponding to the substantia nigra pars
compacta, is the origin of the nigrostriatal dopaminergic system which innervates
predominantly the nucleus caudatus and the putamen (striatum). A minor component
of the striatal innervation originates in the A8 cell group which is located caudally to
the A9 cell group. The nigrostriatal system is thought to be critically involved in the
regulation of movement and also subserves some cognitive processes (Björklund and
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Lindvall 1984). The neuronal cell group A10, corresponding to the ventral tegmental
area, is the predominant source of the mesolimbic pathways. The mesolimbic pathway
innervates mainly the nucleus accumbens and the tuberculum olfactorium and is
considered to be involved in arousal, locomotor activity, reward, motivational and
affective states and euphoria induced by drugs (Björklund and Lindvall 1984; Fuxe et
al. 1985; Koob 1992). The neuronal cell group A10 is also the predominant source of
the mesocortical pathway which innervates mainly the septum, amygdala,
hippocampus, prefrontal cortex and other cortical limbic areas. This pathway is
important in higher cortical functions (Björklund and Lindvall 1984; Fuxe et al. 1985).
In addition to the long-length ascending dopaminergic pathways described above there
are local ultrashort and intermediate length dopaminergic systems such as the
tuberoinfundibular and incertohypothalamic systems (Björklund and Lindvall 1984;
Fuxe et al. 1985; Cooper et al. 1996).
2.2.2. Noradrenergic pathways
There are two major clusterings of noradrenergic cell bodies from which axonal
systems arise to innervate targets throughout the entire neuraxis. The majority of cell
bodies is located in the locus coeruleus, the most important noradrenergic nucleus.
Fibers from the locus coeruleus form five major noradrenergic tracts which send axons
to most areas of the brain, such as the cortices, thalamus, hypothalamus, olfactory
bulbs and cerebellum (Cooper et al. 1996; Feldman et al. 1997). A large number of
noradrenergic neurons lie outside the locus coeruleus where they are loosely scattered
throughout the lateral ventral tegmental fields. The fibers from these neurons
intermingle with those arising from the locus coeruleus, contributing to the innervation
of the forebrain, hypothalamus and other diencephalic structures, mesencephalon and
spinal cord. The whole brain noradrenergic system may thus function as an entity
which when activated inhibits the target cells by hyperpolarizing their cell membranes.
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However, the responses to general arousal are not necessarily similar in different brain
areas because they can be subject to local modulation by other neurons or
neurotransmitters (Cooper et al. 1996; Feldman et al. 1997). The central NA neurons
are suggested to participate in psychoses, in learning and memory, in reinforcement, in
the anxiety-nociception hypothesis and in overall behavioural arousal (Glavin 1985;
Cooper et al. 1996). Furthermore, there is evidence that the central noradrenergic
systems may have a role in the behavioural actions of psychomotor stimulants (Tessel
1990) and opioids (Estler 1973; Kempf et al. 1976; Michaluk et al. 1991).
2.3. Synthesis and metabolism of catecholamines
2.3.1. Dopamine
The hydroxylation of L-tyrosine to L-dihydroxyphenylalanine (L-DOPA) by the
enzyme tyrosine hydroxylase is considered to be the first and most important rate
limiting step in the synthesis of catecholamines. The subsequent decarboxylation of L-
DOPA by aromatic L-amino acid decarboxylase results in the formation of DA. The
activity of tyrosine hydroxylase is regulated by feedback inhibition by L-DOPA, as
well as by DA (Masserano et al. 1989). After its synthesis, DA is transported to storage
vesicles or is metabolised in the cytoplasm (Hoffman et al. 1996).
Ca2+-dependent release of DA from a nerve terminal is thought to occur in response to
invasion of the terminal by an action potential. The extent of DA release appears to be
a function of the rate and the pattern of firing. DA release is also modulated by
presynaptic release modulating DA autoreceptors. DA nerve terminals possess high
affinity DA uptake sites which play an important role in the inactivation and recycling
of DA released into the synaptic cleft by actively pumping extracellular DA back into
the nerve terminal (Fuxe et al. 1985; Cooper et al. 1996).
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The metabolism of DA can take place in the synaptic cleft, in the cytoplasm of nerve
terminal and in glial cells. The main enzymes metabolising DA are monoamine
oxidase (MAO), catechol-O-methyltransferase (COMT) and aldehyde dehydrogenase
(AH), and the main metabolites of DA are 3,4-dihydroxyphenylacetic acid (DOPAC),
3-methoxytyramine (3-MT) and homovanillic acid (HVA) (Fig. 2-2). The DA
metabolising enzymes are differently localised in the cells. COMT is found both in
membrane bound form in postsynaptic neurons, and in cytoplasmic soluble form in the
extraneuronal tissue like glial cells (Männistö et al. 1992). MAO is located both intra-
and extraneuronally (Cooper et al. 1996). DA released into the synaptic cleft can be
inactivated both by reuptake into the dopaminergic nerve endings and by extracellular
inactivation. In dopaminergic nerve terminals, DA is metabolised intraneuronally to
corresponding aldehyde by MAO. The aldehyde is subsequently oxidised to DOPAC
by AH (Wood and Altar 1988; Cooper et al. 1996). In the rat brain, about 90% of DA
is metabolised to DOPAC (Westerink and Spaan 1982a). DOPAC is suggested to be a
poor indicator of the release of DA, while the striatal concentration of DOPAC seems
to be an index of DA synthesis, since a substantial amount of DOPAC is derived from
a newly formed pool of DA (Zetterström et al. 1988). After diffusing out of the
neurons, DOPAC can be further metabolised to HVA by COMT. As HVA is
predominantly derived from O-methylation of DOPAC, the changes in the tissue and
extracellular content of HVA follow those of DOPAC (Westerink 1985). The
extraneuronal DA metabolite, 3-MT, is formed from released DA by COMT and is
further metabolised to HVA by MAO and AH. Thus, tissue contents, as well as
extracellular concentration of 3-MT, can be used as an index of DA release (Kehr
1976; Westerink and Spaan 1982a,b; Westerink et al. 1987; Haikala and Ahtee 1988;
Wood and Altar 1988; Wood 1993), provided that compounds altering DA release do
not alter the function of the DA metabolising enzymes or the transport system of the
metabolites from the brain. In order to evaluate the functional state of the
dopaminergic neurons, the depletion of DA after inhibition of catecholamine synthesis
by tyrosine hydroxylase inhibitor α-methyl-p-tyrosine (αMT) can be measured as well;
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Fig. 2-2. Major routes for catabolism of dopamine (modified from Feldman et al. 1997).
Abbreviations: MAO, monoamine oxidase; COMT, catechol-O-methyltransferase.
the rate of catecholamine depletion after synthesis inhibition is used as an index of
catecholamine turnover (Brodie et al. 1966).
After sacrificing an animal by decapitation, DA is metabolised rapidly as COMT
continues to be active; in rats post-mortem tissue 3-MT concentration increases
quickly, and therefore the microwave irradiation, which inactivates COMT, is
considered the preferred method of sacrifice (Westerink and Spaan 1982a,b; Vulto et
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al. 1986; Wood and Altar 1988). However, in mouse striatum the steady state content
of 3-MT is several times larger and the turnover as well as the post-mortem formation
of 3-MT are clearly slower than in rats (Haikala 1986; Wood et al. 1988). Furthermore,
if the experimental conditions are carefully controlled and the dissection time is
constant and sufficiently short, the post-mortem elevation of 3-MT concentration is not
substantial (Haikala 1986; Wood et al. 1988).
In vivo microdialysis has proven to be a useful technique to measure the concentrations
of DA and its metabolites in the rat brain (Benveniste and Hüttermeier 1990).
However, there are only a few studies in which in vivo microdialysis has been utilized
to determine the effects of drugs on DA metabolism in mice, as accurate implantation
of microdialysis probes in mouse brain, as well as reaching the sensitivity to measure
DA or its metabolites in the extracellular fluid, can be difficult to achieve. 
2.3.2. Noradrenaline
In addition to its role as a neurotransmitter, DA serves as the precursor of NA. Thus,
the biosynthesis pathway for the formation of NA is shared with that of DA; NA is
formed from DA by the enzyme dopamine-ß-hydroxylase, localised primarily in the
membrane of the amine storage granules. NA can be further methylated to adrenaline
by the enzyme phenylethanolamine-N-methyltransferase. NA is stored in the nerve
endings in granules, which contain NA and adenosine triphosphate (ATP) in a molar
ratio of NA to ATP of about 4:1 (Cooper et al. 1996; Feldman et al. 1997).
The stimulus-evoked release of NA from the nerve terminal is Ca2+ -dependent.
Catecholamines, acetylcholine, adenosine, prostaglandins and various peptides have
been implicated in the modulation of NA release via local actions on nerve terminals
(Glavin 1985). In addition, the role of presynaptic receptors in the modulation of
impulse-induced NA release is important. α2-Adrenergic autoreceptors, as well as
22
muscarinic, opioid- and DA-receptors, are suggested to be involved in the inhibition of
NA release (Glavin 1985; Cooper et al. 1996).
About 40-60% of NA released is metabolised enzymatically, while the remainder is
inactivated by uptake into various tissues (Cooper et al. 1996). NA metabolism may
start either with deamination or O-methylation (Fig. 2-3). The intraneuronal metabolite
of NA is 3,4-dihydroxyphenylethyleneglycol (DOPEG); NA is first converted to 3,4-
dihydroxyphenylglycolaldehyde by MAO, then to DOPEG by aldehyde reductase.
DOPEG is further O-methylated by COMT to 3-methoxy-4-
hydroxyphenylethyleneglycol (MOPEG). On its release from the neurons, NA is first
metabolised by COMT, yielding normetanephrine. Normetanephrine is converted
either into vanillylmandelic acid by MAO and AH, or into MOPEG by MAO and
aldehyde reductase (Cooper et al. 1996; Feldman et al. 1997).
The pattern of NA metabolism differs among animal species. In the rat brain, MOPEG
is readily conjugated with sulphate and in the rat MOPEG exists mostly as the sulphate
conjugate (Schanberg et al. 1968; Meek and Neff 1972). However, in the mouse brain
the free MOPEG predominates (Ceasar et al. 1974). Of the MOPEG intermediates,
DOPEG has been suggested to be a good indicator of NA turnover (Ceasar et al. 1974;
Li et al. 1981, 1986), but, due to its low concentration in various mouse brain areas,
the measurement of DOPEG is difficult. The concentration of free MOPEG has been
used as the functional index of cerebral NA turnover and release in mice (Sharman
1969; Ceasar et al. 1974; Heal et al. 1989). Similarly as for DA (section 2.3.1.) the rate
of NA depletion after inhibition of catecholamine synthesis by αMT can be used as an
index of NA turnover (Brodie et al. 1966).
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Fig. 2-3. Major routes for cataboliusm of noradrenaline (modified from Feldman et al. 1997).
Abbreviations: MAO, monoamine oxidase; COMT, catechol-O-methyltransferase.
2.4. α-Adrenoceptors
Adrenoceptors can be defined as cell membrane receptors, belonging to the 7-
transmembrane-spanning G-protein-linked family of receptors, which respond to
noradrenaline and adrenaline. Adrenoceptors are divided into two categories, α and ß,
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and α-adrenoceptors are further divided into α1- and α2-adrenoceptors. Three
pharmacological subtypes of the α2-adrenoceptors (α2A, α2B, α2C) have been described
(MacDonald et al. 1997; Docherty 1998). Activation of α2-adrenoceptors leads to
inhibition of adenylyl cyclase, activation of K+-channels and inhibition of Ca2+-
channels (Hoffman et al. 1996; Feldman et al. 1997).
α2-Adrenergic autoreceptors regulate the activity of the noradrenergic neurons in the
locus coeruleus. These receptors are located on nerve terminals as well as on the cell
bodies and/or dendrites, and participate in local and neuronal feedback inhibition
(Cedarbaum and Aghajanian 1977; Glavin 1985). α2-Adrenergic autoreceptors in the
brain have been found to belong to α2A-subtype (Feldman et al. 1997). Activation of
α2-adrenoceptors by NA or by other α2-agonists decreases NA release and firing rate
of the neurons (Starke 1972). Receptor blockade by α2-antagonists increases the firing
rate and responsiveness of neurons to stimulation and promotes the release of NA
(Starke et al. 1975; Freedman and Aghajanian 1984; Scheinin et al. 1988). In addition
to α2-autoreceptors there are α2-receptors located elsewhere than on the noradrenergic
nerves. These α2-heteroreceptors may be involved in the regulation of the release of a
variety of neurotransmitters (Dennis et al. 1987; Trendelenburg et al. 1994; Schlicker
and Göthert 1998).
Clinical uses for various α-adrenoceptor antagonists and agonists have been
established (Hoffman and Lefkowitz 1996). Clonidine, an α2-adrenergic agonist, has
been in clinical use in the treatment of hypertension, as an analgesic and in the
treatment of opioid withdrawal syndrome (Hoffman and Lefkowitz 1996; Feldman et
al. 1997). However, clonidine has affinity also for α1- and imidazoline receptors
(Hoffman and Lefkowitz 1996) and therefore it is not an optimal tool for
pharmacological research. There are differences in the specificity and selectivity of
available α2-adrenoceptor antagonists as well. For instance, RX821002 (2-methoxy-
idazoxan), BRL 44408 and ARC 239 have affinity for non-adrenoceptor imidazoline
receptors and 5-hydroxytryptamine 5-HT1A-autoreceptors (Callado et al. 1996; Meana
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et al. 1996). Furthermore, atipamezole, a selective α2-adrenoceptor antagonist
(Virtanen et al. 1989), can modulate the effects of striatal DA-receptor activation in
rats, increasing motor activity (MacDonald et al. 1996).
Idazoxan is a relatively selective α2-adrenoceptor antagonist (Freedman and
Aghajanian 1984). It increases NA release in cortex and hippocampus of rats (Dennis
et al. 1987; Thomas et al. 1994). Idazoxan also increases the concentration of NA
metabolites in the mouse whole brain (Heal et al. 1989) and in various rat brain areas
(Scatton et al. 1983; Curet et al. 1987). The effects of idazoxan on cortical NA release
in rats are suggested to be mediated primarily by α2-adrenoceptors located on
noradrenergic nerve terminals, rather than by those located postsynaptically,
somatodendritically or on the terminals of other neuronal inputs to the cerebral cortex
(Dennis et al. 1987).
Idazoxan, when administered alone, does not alter the locomotor activity of mice
(Durcan et al. 1989; Chojnacka-Wojcik 1992; Jackson et al. 1992), but alters
amphetamine-, apomorphine- or cocaine-induced changes in locomotor activity in
mice and rats (Dickinson et al. 1988; Jackson et al. 1992; Chen and Reith 1994).
However, there are no studies on the effects of idazoxan on morphine-induced changes
in locomotor activity. In addition to its effects on cerebral NA turnover and release, in
rats idazoxan can stimulate cerebral DA cell firing, as well as cerebral DA turnover
and release (Tian et al. 1991; Grenhoff and Svensson 1993; Nisenbaum and
Abercrombie 1993; Paez and Leibowitz 1993; Chen and Reith 1995; Matsumoto et al.
1998). Furthermore, in addition to α2-adrenoceptors, idazoxan binds to non-
adrenoceptor imidazoline I2-binding sites in the rat, guinea pig and human cerebral
cortex membranes, but not in those of the mouse (Hussain et al. 1993; Miralles et al.
1993). Moreover, idazoxan is an agonist at cerebral 5-HT1A-autoreceptors and has
been reported to decrease cerebral 5-HT metabolism in rats (Llado et al. 1996). Thus,
when used as tools in pharmacological research the possible effects of α2-adrenoceptor
antagonists on other receptors should be taken into consideration.
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2.5. Effects of morphine administration on cerebral catecholamine turnover in
mice
2.5.1. Dopamine
2.5.1.1. Acute morphine administration
Acute systemic morphine administration increases DA turnover and release in the
mouse brain. Acute morphine does not alter the DA concentration in various mouse
brain areas (Ishikawa et al. 1983; Attila et al. 1987; Narita et al. 1992; Funada et al.
1993b, 1994) but it increases the synthesis of DA in the mouse whole brain, in the
cortical brain areas and in the diencephalon (Smith et al. 1970; Rethy et al. 1971;
Rosenman and Smith 1972; Smith et al. 1972; Bloom et al. 1976). Furthermore, acute
morphine administration accelerates the αMT-induced DA depletion in the striatum, as
well as in the cortical areas (Attila et al. 1987; Etemadzadeh 1993). However, in the
experiments of Smith et al. (1972) acute morphine did not alter DA synthesis in the
striatum and Kempf et al. (1976) found that acute morphine administration did not
alter the αMT-induced DA depletion in the striatum. In the experiments of Kovacs et
al. (1983) acute morphine retarded the DA depletion in certain mouse brain nuclei.
Acute morphine administration increases the DOPAC and HVA concentrations in the
mouse whole brain (Fukui and Takagi 1972; Ishikawa et al. 1983), in the striatum
(Kuschinsky and Hornykiewicz 1974; Kääriäinen and Ahtee 1976; De La Baume et al.
1979; Reggiani et al. 1980; Wood et al. 1980; Wood and Richard 1982; Ahtee et al.
1987; Saito 1990; Kunihara et al. 1993) and in cortical and limbic brain areas
(Reggiani et al. 1980; Nabeshima et al. 1985; Narita et al. 1992; Funada et al. 1993b,
1994; Kunihara et al. 1993). However, the effects of acute morphine administration on
cerebral 3-MT concentration may vary in different mouse strains. In the experiments of
Racagni et al. (1979) acute morphine decreased the striatal 3-MT concentration in
DBA mice but increased that in C57BL mice; in Swiss-Hauschke mice the striatal 3-
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MT concentration was increased after acute morphine administration (Wood and
Richard 1982). Furthermore, the effect of acute morphine on the striatal 3-MT
concentration may be dose-dependent, as in ddY mice a small morphine dose
decreased the striatal 3-MT concentration while a large dose increased it (Saito 1990).
In rats, acute morphine increases the αMT-induced depletion of striatal and limbic DA
(Moleman and Bruinvels 1979; Alper et al. 1980; Attila and Ahtee 1984b; Frink et al.
1996). Furthermore, acute morphine increases the striatal and limbic DOPAC and
HVA concentrations (Ahtee and Kääriäinen 1973; Westerink 1979; Alper et al. 1980;
Wood et al. 1980; Ahtee et al. 1989, 1990; Honkanen et al. 1994; Piepponen and
Ahtee 1995; Wakabayashi et al. 1995; Frink et al. 1996). However, acute morphine has
been reported to decrease or not to alter (Wood and Richard 1982; Ahtee et al. 1989,
1990) or to increase (Honkanen et al. 1994) the striatal or limbic 3-MT concentration
in rats. In in vivo microdialysis studies, acute systemic morphine increases the release
of DA in the ventral striatum (Acquas et al. 1991). Furthermore, systemic morphine
increases the firing rate of mesencephalic dopaminergic neurons (Gysling and Wang
1983; Matthews and German 1984). However, morphine when administered locally,
has been shown to inhibit the release of striatal DA (Rossetti et al. 1990; Piepponen et
al. 1999) and it has been suggested that systemic and locally administered morphine
may affect DA release in opposite directions in rats (Rossetti et al. 1990). There are no
in vivo microdialysis studies on the effects of acute morphine on cerebral DA release
in mice.
2.5.1.2. Chronic morphine administration
Morphine withdrawal. In  mice, after withdrawal from chronic morphine treatment, the
activity of cerebral dopaminergic neurons is attenuated. A short 6 h withdrawal from a
2- or 3-day chronic morphine treatment does not alter the synthesis rate of DA in the
mouse whole brain but after a longer withdrawal period the synthesis rate is retarded
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(Smith et al. 1972; Rosenman and Smith 1972). Furthermore, 1-day withdrawal from a
3- or 5-day chronic morphine treatment retards the αMT-induced DA depletion in the
striatum and in the cortical areas (Etemadzadeh 1993, 1994). Shortly after cessation of
the chronic morphine treatment, the cerebral DOPAC and HVA concentrations are not
altered (Fukui and Takagi 1972) and the striatal HVA concentration may be even
slightly increased (De La Baume et al. 1979). However, after a withdrawal period
longer than 12 h the striatal HVA concentration is decreased (De La Baume et al.
1979; Ahtee et al. 1987); in these experiments the duration of the chronic morphine
treatment was 3 to 8 days. In mice implanted with morphine pellets for 4 days,
naloxone-precipitated withdrawal did not alter the striatal DOPAC/DA ratio but
decreased the striatal DA concentration (Navarro et al. 1992). It thus appears that the
activity of the cerebral dopaminergic systems in mice is decreased only after
sufficiently long chronic morphine treatment and withdrawal. On the other hand, the
effects of withdrawal from chronic morphine treatment on cerebral DA turnover may
slightly differ in various brain areas, as naloxone-precipitated withdrawal in mice
implanted with morphine pellets for 4 days retarded the αMT-induced DA depletion in
the substantia nigra and in the ventral tegmental area but increased that in the nucleus
accumbens (Kovacs et al. 1983).
In rats, the activity of cerebral dopaminergic neurons also decreases after chronic
morphine treatment and withdrawal; this, however, is observed after longer chronic
morphine treatment and withdrawal than in mice (Attila and Ahtee 1983, 1984b). The
αMT-induced DA depletion is retarded first in limbic areas and after longer chronic
treatment and withdrawal in the striatum (Attila and Ahtee 1983, 1984b). Furthermore,
the DOPAC and HVA concentrations are decreased in several rat brain areas after
sufficiently long chronic morphine treatment and withdrawal (Ahtee et al. 1989;
Wakabayashi et al. 1995). In microdialysis studies, the release of mesolimbic DA has
been found to be decreased after chronic morphine treatment and withdrawal (Acquas
et al. 1991; Acquas and Di Chiara 1992). Moreover, after morphine withdrawal the
firing rate of mesolimbic dopaminergic neurons is reduced (Diana et al. 1999).
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Morphine challenge dose. There is tolerance to the effects of acute morphine on
cerebral DA turnover and release in mice shortly after the withdrawal. This tolerance
has been shown by the effects of acute morphine challenge on DA synthesis in the
whole brain of mice withdrawn for 6 h from a 2-10 day chronic morphine treatment
(Rosenman and Smith 1972; Smith et al. 1972). Furthermore, there is tolerance to the
effects of acute morphine on αMT-induced DA depletion in cortical brain areas in
mice withdrawn for 1 or 2 days from a 5-day chronic morphine treatment
(Etemadzadeh 1993). Moreover, immediately after 8 days' chronic morphine treatment,
tolerance was found towards the acute morphine-induced increase of DOPAC and
HVA concentrations in the mouse whole brain (Fukui and Takagi 1972). In the above-
mentioned studies the withdrawal periods were relatively short (0-2 days). In the
experiments of Ahtee et al. (1987), tolerance to the striatal HVA concentration
increasing effect of acute morphine was no longer evident after a 3-day withdrawal
from a 4-day chronic morphine treatment, although after a similar withdrawal period
from a 3-day chronic morphine treatment there was tolerance; in these experiments the
fall of striatal HVA concentration was more pronounced after a 4-day chronic
morphine treatment than after a 3-day one.
In rats, it has been found that after chronic morphine treatment there is a short lasting
tolerance towards the mesolimbic DA release increasing effect of acute morphine
(Acquas et al. 1991; Acquas and Di Chiara 1992). However, after sufficiently long
repeated morphine treatment and withdrawal a morphine challenge dose increases the
synthesis of cerebral DA (Clouet and Ratner 1970), as well as accelerates the striatal
and limbic αMT-induced DA depletion (Attila and Ahtee 1983, 1984b) more than in
naive controls. Furthermore, in rats on withdrawal from chronic morphine treatment, a
morphine challenge dose increases the striatal and limbic DOPAC and HVA
concentrations similarly as in controls and, in contrast to controls, increases the striatal
3-MT concentration (Ahtee et al. 1989, 1990); in the experiments of Honkanen et al.
(1994), acute morphine increased the striatal 3-MT and HVA concentrations and the
limbic 3-MT concentration to a greater extent in morphine-withdrawn rats than in
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control rats. The sensitization to the acute morphine-induced increase of striatal and
limbic DA release after sufficiently long chronic morphine treatment and withdrawal
has been verified in microdialysis studies (Acquas and Di Chiara 1992; Spanagel and
Shippenberg 1993). Furthermore, morphine challenge dose increases the firing rate of
mesolimbic dopaminergic neurons to a greater extent in rats withdrawn from chronic
morphine treatment than in control rats (Diana et al. 1999). The results of Ahtee et al.
(1987) suggest that also mice could be sensitized to the DA release increasing effect of
acute morphine.
2.5.2. Noradrenaline
2.5.2.1. Acute morphine administration
Acute morphine administration increases the synthesis of NA in the mouse whole brain
and cortical areas (Rosenman and Smith 1972; Smith et al. 1972; Bloom et al. 1976) as
well as accelerates the αMT-induced NA depletion in the whole brain, hypothalamus,
lower brain stem and cortical areas (Attila et al. 1987; Etemadzadeh 1993, 1994).
However, the effect of acute morphine on cerebral NA turnover may differ in various
mouse strains and brain areas. Although acute morphine increased the αMT-induced
NA depletion in the lower brain stem of C57BL and Balb mice, it did not alter the
hypothalamic NA turnover of C57BL, Balb and DBA mice (Kempf et al. 1976). There
are not many studies on the effects of acute morphine on the free MOPEG
concentration in the mouse brain. Acute morphine increased the free MOPEG
concentration in the striatum of ddY mice, but since the basal striatal free MOPEG
content is small it was suggested that this might not be a direct action of morphine
(Saito 1990).
In rats, acute morphine decreases the firing of the noradrenergic neurons in the locus
coeruleus (Korf et al. 1974; Aghajanian 1978) and decreases the efflux of NA from
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locus coeruleus slices (Guyenet and Byrum 1985; Jorm and Stamford 1995). However,
the effects of morphine on NA turnover and release vary in different rat brain areas.
Acute morphine has been reported to accelerate the αMT-induced NA depletion in the
lower brain stem (Sugrue 1974; Paalzow and Paalzow 1975). In the studies of Attila
and Ahtee (1983, 1984a) and Attila (1989), the NA depletion was observed to be
accelerated by acute morphine in the lower brain stem but retarded in most other brain
areas. In the experiments of Ota et al. (1991), the NA concentration was reduced by
acute morphine administration in the hypothalamus and in the locus coeruleus. Acute
morphine increases the sulphated MOPEG concentration in most rat brain areas and in
the rat whole brain, but not in the cortical areas (Roffman et al. 1975; Tanaka et al.
1983; Ahtee et al. 1989; Attila 1989). In in vivo microdialysis studies acute morphine
has been shown to reduce NA release in rat hippocampus (Done et al. 1992;
Matsumoto et al. 1994). Because in mice acute morphine increases NA turnover and
release in most brain areas, the effects of acute morphine on cerebral NA turnover and
release may differ in mice and rats.
2.5.2.2. Chronic morphine administration
Morphine withdrawal. The effects of morphine withdrawal on cerebral NA turnover
and release in mice appear to be relatively small. Six-hour withdrawal from a 2-3 day
or 10-day chronic morphine treatment did not alter or even decreased the synthesis rate
of NA in the mouse whole brain (Rosenman and Smith 1972; Smith et al. 1972).
Furthermore, the αMT-induced NA depletion was not altered in the lower brain stem,
cortical areas or hypothalamus, of mice withdrawn for 1-3 days from a 3-5 day chronic
morphine treatment (Etemadzadeh 1993, 1994). Neither was the cortical free MOPEG
concentration altered 2 hours after a 5-day chronic morphine treatment, but naloxone-
precipitated withdrawal increased the cortical MOPEG/NA ratio (Funada et al. 1993a;
Suzuki et al. 1995).
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The effects of chronic morphine treatment and withdrawal on cerebral NA turnover
and release may differ in mice and rats, as in rats the activity of locus coeruleus
neurons is increased during morphine withdrawal (Rasmussen et al. 1990). The αMT-
induced NA depletion is accelerated in various brain areas of rats withdrawn from
chronic morphine treatment (Gunne et al. 1969; Attila and Ahtee 1983, 1984a).
Furthermore, the NA concentration is decreased and the free MOPEG or sulphated
MOPEG concentration is increased in most rat brain areas after spontaneous or
naloxone-precipitated withdrawal (Gramsch and Bläsig 1976; Crawley et al. 1979;
Swann et al. 1983; Ahtee et al. 1989). The increased release of NA from rat
hippocampus after naloxone-precipitated withdrawal has been shown by an in vivo
microdialysis study as well (Silverstone et al. 1992).
Morphine challenge dose. It is evident that during chronic morphine treatment,
tolerance develops towards the acute morphine-induced increase of cerebral NA
turnover and release in mice. This is suggested by reduced response to the acute
morphine-induced increase in synthesis of NA in the mouse whole brain after a 6 h
withdrawal from 2-3 day or 10 day chronic morphine treatment (Rosenman and Smith
1972; Smith et al. 1972). Furthermore, tolerance towards the acute morphine-induced
acceleration of αMT-induced NA depletion is found in the lower brain stem,
hypothalamus and cortical areas of mice withdrawn for 1 or 2 days from 3-day or 5-
day chronic morphine treatment (Etemadzadeh 1993, 1994); in these experiments,
however, tolerance was not found after a 5-day chronic morphine treatment and 7-day
withdrawal, suggesting loss of tolerance after longer withdrawal periods. There are no
studies on the development of tolerance towards the acute morphine-induced increase
of free MOPEG concentration in various mouse brain areas.
In rats, tolerance develops towards the acute morphine-induced acceleration of αMT-
induced NA depletion in the lower brain stem but not towards its retardation in the
cortical areas (Attila and Ahtee 1983, 1984a; Ahtee et al. 1989). Furthermore, in the rat
brain tolerance develops towards the acute morphine-induced increase in free MOPEG
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or sulphated MOPEG concentration (Roffman et al. 1977; Ahtee et al. 1989) and rats
implanted with morphine pellets are tolerant to the acute morphine-induced decrease
of hypothalamic NA concentration (Milanes et al. 1993). Thus, in contrast to mice, in
which even after a chronic morphine treatment morphine challenge accelerates NA
turnover and release, although less than in naive mice, in most brain areas of
morphine-withdrawn rats morphine challenge either does not alter cerebral NA
turnover and release or decreases it.
2.6. Effects of morphine administration on the locomotor activity of mice
2.6.1. Acute morphine administration
Morphine and other opioids may induce many behavioural effects in mice, including
those concerning social behaviour such as offensive aggression, defense-escape or
ambivalent behaviour (Hecht and Schiφrring 1979; D'Amato and Castellano 1989).
Morphine administration may increase or decrease the locomotor activity of mice or
even induce catalepsy (Bläsig and Herz 1980). However, it has been repeatedly shown
that in most mouse strains acute morphine administration dose-dependently induces
locomotor hyperactivity.
The effects of morphine administration on locomotor activity of mice may depend on
the mouse strain, the dose regimen (dosage and/or acute or chronic administration),
and the time between morphine administration and the measurement of the activity.
Furthermore, the effects of acute morphine administration on the locomotor activity of
mice may depend on the spontaneous locomotor activity which may vary in different
mouse strains (Kempf et al. 1974, 1976; Marona-Lewicka and Vetulani 1989).
Moreover, stress induced by handling may alter the locomotor response to morphine as
well (Messiha et al. 1990). The locomotor activity increasing effects of morphine, as
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well as its decreasing effects, can be antagonised by the opioid receptor antagonist
naloxone, suggesting that these effects are mediated by opioid receptors (Brady and
Holtzman 1981).
As summarised in Table 2-1, systemic acute morphine administration induces
locomotor hyperactivity in most mouse strains. In addition to C57BL, Swiss, NMRI
and Balb mouse strains, acute morphine induces locomotor hyperactivity in C3H
(Brase et al. 1977; Kuribara and Tadokoro 1989), in ICR (Brase et al. 1977; Kuribara
and Tadokoro 1989; Stone et al. 1990; Kunihara et al. 1993; Kamei and Saito 1996)
and in ddY and dd mice (Kuribara and Tadokoro 1989; Funada et al. 1993b, 1994;
Narita et al. 1993; Kuribara 1995, 1996, 1997). However, acute morphine-induced
locomotor hyperactivity can be preceded by a decrease in the activity in Swiss (Carrol
and Sharp 1972), in NMRI (Hecht and Schiφrring 1979) and in CFLP mice (Szekely et
al. 1980). Furthermore, while the references cited in Table 2-1 show that acute
morphine does not alter the locomotor activity of DBA mice, Gwynn and Domino
(1984) found that after 1 h initial decrease in locomotor activity, acute morphine
induced locomotor hyperactivity in these mice. In the experiments of VanderWende
and Spoerlein (1979), the acute morphine-induced locomotor hyperactivity of CF-1
mice was preceded by catalepsy. Because the locomotor hyperactivity induced by acute
morphine peaks at 60-120 min after morphine administration (Carroll and Sharp 1972;
Estler 1973; Kuschinsky and Hornykiewicz 1974; Shuster et al. 1975; Funada et al.
1993b; Kunihara et al. 1993), the differences in reported effects of morphine on the
locomotor activity may be partly due to the duration of the observation period.
Furthermore, as there is an increase in the spontaneous locomotor activity of mice
when placed in the locomotor activity cage they can be habituated before measurement
to reduce the effect of the exploration phase (Kuschinsky and Hornykiewicz 1974;
Brase et al. 1977; Racagni et al. 1979; Longoni et al. 1987; Mφrland et al. 1994), or the
locomotor activity can be measured after the exploration phase (Kunihara et al. 1993).
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Table 2-1. Effect of acute s.c. or i.p. morphine administration on the locomotor activity of C57BL, Swiss
or Swiss-Webster (Swiss), NMRI, Balb and DBA mice.
Strain Effect Dose Reference
                                                                                                                                           
C57BL ↑ 3.2-160 mg/kg Oliverio and Castellano 1974; Castellano and Oliverio
1975; Castellano et al. 1975; Oliverio et al. 1975; Brase
et al. 1977; Racagni et al. 1979; Filibeck et al. 1980;
Brunello et al. 1984; Longoni et al. 1987; Kuribara and
Tadokoro 1989; Marona-Lewicka and Vetulani 1989;
Mφrland et al. 1994; Alkana et al. 1995
± 12.5-40 mg/kg Shuster et al. 1975
± 20-80 mg/kg Eidelberg et al. 1975
↓ 10 mg/kg Eidelberg et al. 1975
Swiss ↑ 5-160 mg/kg Rethy et al. 1971; Kuschinsky and Hornykiewicz 1974;
Parker 1974; Brase et al. 1977
↓↑ 25 mg/kg Carroll and Sharp 1972
↑1 20 mg/kg Michaluk et al. 1991
↓ 10 mg/kg Eidelberg et al. 1975
↑ 20-80 mg/kg Eidelberg et al. 1975
± 0.5-5 mg/kg D'Amato and Castellano 1989
NMRI ↑ 3-50 mg/kg Estler 1973; Ahtee et al. 1987, Attila et al. 1987
↑ 100-150 mg/kg Hecht and Schiφrring 1979
↓↑ 5-10 mg/kg Hecht and Schiφrring 1979
Balb ↑ 5-40 mg/kg Oliverio and Castellano 1974; Castellano and Oliverio
1975; Shuster et al. 1975; Kuribara and Tadokoro 1989
↓ 10 mg/kg Eidelberg et al. 1975
↑ 20-80 mg/kg Eidelberg et al. 1975
± 20 mg/kg Marona-Lewicka and Vetulani 1989
DBA ± 5-160 mg/kg Oliverio and Castellano 1974; Castellano and Oliverio
1975; Castellano et al. 1975; Brase et al. 1977; Racagni
et al. 1979
                                                                                                                                            
↑ increase in locomotor activity, ↓ decrease in locomotor activity, ↓↑ initial decrease in locomotor
activity followed by an increase in activity, ± no change in locomotor activity.
1 Increase in activity in 25 % of mice, decrease in activity in 20 % of mice.
The locomotor response to acute morphine administration depends on the dose used. In
C57BL mice, acute morphine at 5-160 mg/kg dose-dependently induces locomotor
hyperactivity (Brase et al. 1977; Brunello et al. 1984; Gwynn and Domino 1984;
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Longoni et al. 1987). However, it has also been reported that in C57BL mice small
morphine doses either do not alter the locomotor activity or even decrease it and large
doses do not alter the activity (Eidelberg et al. 1975; Shuster et al. 1975). Similar dose-
dependent locomotor responses to morphine administration have been found in ICR
and ddY mice (Eidelberg et al. 1975; Saito 1990) and in Swiss and Balb mice small
morphine doses may decrease the activity and large doses increase it (Eidelberg et al.
1975).
In the studies described earlier in this section, morphine was administered i.p. or s.c.
When administered i.c.v. to C57BL, Swiss or DBA mice (Frigeni et al. 1978) or to
ddY mice (Funada et al. 1993b; Narita et al. 1993), a dose-dependent increase in
locomotor activity was observed. However, in the studies of Bhargava (1978) small
doses of morphine induced locomotor hyperactivity in Swiss mice while large doses
decreased the activity. These results agree with studies using rats as it has been shown
that in rats acute morphine induces catalepsy and a decrease in locomotor activity, or
there is a biphasic effect, i.e. an initial depression of locomotor activity followed by a
period of hyperactivity; only small morphine doses induce locomotor hyperactivity
(Fog 1970; Babbini and Davis 1972; Kuschinsky 1976; Brady and Holtzman 1981;
Havemann and Kuschinsky 1982; Oliverio et al. 1983). Thus, although the effects of
acute morphine administration on locomotor activity may depend on the dose used and
the mouse strain, these effects differ in mice and rats, as in mice the most predominant
effect is locomotor hyperactivity and in rats this effect is a decrease in activity.
2.6.2. Chronic morphine administration
Morphine withdrawal. There are only a few studies on the effects of withdrawal from
chronic morphine treatment on the spontaneous locomotor activity of mice. The
studies of Rethy et al. (1971) and Oliverio and Castellano (1974) suggest that
withdrawal from chronic morphine treatment does not alter the activity. On the other
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hand, the spontaneous locomotor activity was decreased in mice implanted with
morphine pellets for 4 days (Navarro et al. 1992). In rats on withdrawal from
morphine, the locomotor activity is reduced (Van der Laan and Jansen van't Land
1992).
Morphine challenge dose. When morphine challenge dose is given to mice during
chronic morphine treatment or after a short withdrawal period there is tolerance
towards the acute morphine-induced locomotor hyperactivity. This was shown when a
morphine challenge dose was given to Swiss mice withdrawn for 4-8 h from a 2-day
chronic morphine treatment (Rethy et al. 1971) and when a morphine challenge was
given after a 2-day chronic morphine treatment (no withdrawal period) to C57BL or
Balb mice (Oliverio and Castellano 1974). Furthermore, tolerance to the acute
morphine-induced locomotor hyperactivity was found in mice implanted with
morphine pellets for 4 days (Ülkü et al. 1980).
However, it is apparent that after a longer withdrawal period, tolerance to the acute
morphine-induced locomotor hyperactivity disappears. This is suggested by the
experiments of Ahtee et al. (1987) in which tolerance to the acute morphine-induced
locomotor hyperactivity of NMRI mice was found at 1-day withdrawal from 3- or 4-
day chronic morphine treatment but no longer at 3-day withdrawal. Furthermore,
although tolerance was found after an intermittent administration of morphine for 15
or 21 days at short 3 h and 6 h dosage intervals, after longer dosage intervals of 24 h -
4 days, dd mice were stimulated more by the acute morphine dose than when they
received morphine for the first time (Kuribara 1995, 1996, 1997); similar stimulation
was found after intermittent administration of morphine at 3-4 day intervals in C57BL,
C3H, ICR and Balb mice as well, but not in DBA mice (Kuribara and Tadokoro 1989).
Moreover, while tolerance was found after a 20-day chronic morphine treatment and a
short 6 h withdrawal period, after a 40 h - 10 day withdrawal period, a morphine
challenge dose increased the locomotor activity of NMRI mice to a greater extent than
in control mice (Fernandes et al. 1977). Gwynn and Domino (1984) found an
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enhancement of the acute morphine-induced locomotor hyperactivity after a 7-day
chronic morphine treatment and 12 h withdrawal in C57BL and DBA mice.
The above-described studies give evidence that in mice the locomotor activity
increasing effect of acute morphine may be enhanced after sufficiently long chronic
morphine treatment and withdrawal, similarly as it has been shown in rats that after
chronic administration of morphine and other opioids, acute opioid challenge induces
progressively more pronounced motor stimulation than in naive controls (Babbini and
Davis 1972; Ahtee 1974; Kuschinsky 1976; Finne et al. 1977; Ahtee 1978; Pert 1978;
Carlson and Seeger 1982; Kalivas and Duffy 1987; Vezina et al. 1987).
2.7. Behavioural sensitization
When large doses of morphine or other opioids are administered repeatedly to rats,
tolerance develops towards the acute opioid-induced decrease in locomotor activity
(Ahtee 1974; Vasko and Domino 1978; Brady and Holtzman 1981; Rauhala et al.
1995). Furthermore, after repeated morphine administration the locomotor activity
increasing effect induced by small doses of morphine is increased (Kalivas and Duffy
1987; Vezina et al. 1987; Kalivas and Stewart 1991). The phenomenon, sensitization
or reverse tolerance to the acute opioid-induced locomotor hyperactivity is termed
behavioural sensitization (Kalivas et al. 1988; Robinson and Berridge 1993; Spanagel
and Shippenberg 1993). The sensitization may be due to tolerance towards the
depressant effects of morphine or due to sensitization to the stimulant effects of
morphine (Vezina and Stewart 1984); the differential development of tolerance to the
stimulant and depressant effects of morphine may be mediated by different neuronal
mechanisms (Brady and Holtzman 1981). Behavioural sensitization can be maintained
for months after morphine administration, and the neuronal mechanisms involved in
the sensitization have been associated with drug dependence, craving and relapse
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(Bartoletti et al. 1983; Robinson and Berridge 1993; Spanagel and Shippenberg 1993).
The reinforcing properties of addictive drugs are considered important in the
development of dependence (Koob and Bloom 1988; Robinson and Berridge 1993),
and the role of the mesolimbic dopaminergic systems is considered important in the
mediation of the reinforcing properties of these drugs (Wise and Bozarth 1987;
Robinson and Berridge 1993). While the actual mechanisms involved in the
sensitization are not fully clarified there is evidence of the involvement of
dopaminergic systems in the sensitization, common for many various addictive drugs
(Ahtee and Attila 1987; Kalivas and Stewart 1991; Robinson and Berridge 1993). The
mechanisms may include increased release of DA, increased sensitivity of DA
receptors and of their transduction systems, and changes in the functions of other
neurotransmitter systems (Robinson and Berridge 1993).
The effect of morphine and other opioids on DA release is indirect and results from the
disinhibition of dopaminergic neurons. Opioids hyperpolarize GABAergic neurons
that tonically inhibit the activity of dopaminergic neurons (Gysling and Wang 1983;
Johnson and North 1992). It has been suggested that the acute motor stimulant effects
of morphine are mediated mainly by activation of µ-opioid receptors located within the
mesolimbic dopaminergic pathway and a subsequent increase of DA release in the
nucleus accumbens, the major projection site of mesolimbic DA neurons (Kalivas et
al. 1983; Leone et al. 1991; Devine et al. 1993;  Spanagel and Shippenberg 1993).
Acute morphine increases the synthesis and metabolism of DA more in the limbic area
than in the striatum of rats and after repeated morphine administration the mesolimbic
dopaminergic system appears to be more easily sensitized than the nigrostriatal one
(Attila and Ahtee 1983, 1984; Ahtee and Attila 1987; Vezina et al. 1987).
There are two phases in the development of opioid-induced behavioural sensitization,
induction and expression. There is evidence that in rats the induction of the
behavioural sensitization can be due to changes in the dopaminergic neurons in the
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ventral tegmental area, as repeated administration of opioids to this area induce
locomotor sensitization (Joyce and Iversen 1979; Vezina and Stewart 1984; Vezina et
al. 1987; Kalivas and Duffy 1990), and systemic morphine administration-induced
sensitization can be blocked by naltrexone administered locally to the ventral
tegmental area but not to the nucleus accumbens (Kalivas and Duffy 1987). In
addition, µ-opioid receptor agonists, when administered locally to the nucleus
accumbens, induce locomotor hyperactivity but sensitization does not develop after
repeated administration (Vezina et al. 1987). However, the nucleus accumbens may be
crucial in the expression of the sensitization, as after repeated systemic morphine
administration and withdrawal there is a temporal relationship between the behavioural
sensitization and increased DA release in the nucleus accumbens (Kalivas and Stewart
1991; Spanagel et al. 1993). On the other hand, it has been suggested that the
morphine-induced locomotor hyperactivity in rats may be partially DA-independent
and neurotransmitters other than DA have been suggested to be associated with the
induction or expression of behavioural sensitization in rats (Pert and Sivit 1977;
Kalivas et al. 1983; Bunney et al. 1984; Spanagel et al. 1993). Furthermore, there is
evidence of similar sensitization to the acute morphine-induced locomotor
hyperactivity in mice as in rats (section 2.6.2.) but despite its suggested role in the
induction of morphine sensitization (Kuribara 1995) the involvement of the cerebral
dopaminergic systems in the sensitization phenomenon in mice has not been similarly
established as in rats.
2.8. Role of cerebral dopaminergic and noradrenergic transmission in the
morphine-induced changes of locomotor activity in mice
2.8.1. Locomotor activity and cerebral dopamine
The changes in locomotor activity induced by morphine and other opioids have been
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ascribed in mice to the opioid-induced alteration of catecholamine turnover and release
in striatum and in limbic and cortical brain areas (Kempf et al. 1974, 1976; Strömbom
1976; Bläsig and Herz 1980; Havemann and Kuschinsky 1982; Oliverio et al. 1983;
Messiha et al. 1990; Navarro et al. 1992; Kunihara et al. 1993).
The role of cerebral dopaminergic systems in the mediation of the effects of opioids on
motor behaviour is well established. It is thought that the behaviour-stimulant effect of
acute morphine administration in mice is caused by an increase in dopaminergic
transmission through an action on opioid receptors (Kuschinsky and Hornykiewicz
1974; Kuschinsky 1976; Bläsig and Herz 1980; Reggiani et al. 1980; Oliverio et al.
1983; Kunihara et al. 1993; Funada et al. 1993b; Spanagel et al. 1996). The crucial role
of cerebral dopaminergic systems in the acute morphine-induced locomotor
hyperactivity in mice is further supported by studies in which co-administration of D1-
receptor antagonist SCH 23390 with morphine antagonized the acute morphine-
induced locomotor hyperactivity in C57BL (Longoni et al. 1987) and in ddY mice
(Funada et al. 1994). Furthermore, D2-receptor agonist quinpirole reduced the acute
morphine-induced locomotor hyperactivity and D1-receptor agonist SKF 38393
increased it in ddY mice (Funada et al. 1994). The investigators suggested that the
activation of D1-receptors in the limbic forebrain may play an important role in the
expression of acute morphine-induced hyperlocomotion in mice.
There are differences in the effects of acute morphine administration on locomotor
activity in mice and rats (section 2.6.1.). Moreover, the effects of acute morphine
administration on locomotor activity and striatal 3-MT concentration may differ in
various mouse strains. In C57BL mice acute morphine administration increased the
striatal 3-MT concentration as well as locomotor activity while in DBA mice the
locomotor activity was not altered and the striatal 3-MT concentration was decreased
by acute morphine (Racagni et al. 1979). Furthermore, in the experiments of Wood et
al. (1980), as well as Wood and Richard (1982), acute morphine administration
increased the striatal 3-MT, DOPAC and HVA concentrations in Swiss mice in which
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acute morphine induces locomotor hyperactivity. In ddY mice, a small morphine dose
decreased the locomotor activity and the striatal 3-MT concentration at 10 min after
morphine administration while at 1 h after the administration neither the 3-MT
concentration nor locomotor activity were altered; a larger morphine dose increased
locomotor activity and the 3-MT concentration at 10 min and 1 h after morphine
administration (Saito 1990). Furthermore, acute i.c.v. administration of morphine
increased both the locomotor activity and the DOPAC and HVA concentrations in the
ddY mouse limbic forebrain, including the nucleus accumbens (Funada et al. 1994).
These results suggest that at least in C57BL, Swiss and ddY mice, the acute morphine-
induced locomotor hyperactivity may be related to the morphine-induced increase of
striatal and/or limbic DA release.
Although there is tolerance to the cerebral DA turnover and release increasing effect of
acute morphine in mice shortly after its withdrawal, the response to the morphine
challenge-induced increase of striatal HVA concentration is regained after sufficiently
long chronic morphine treatment and withdrawal (section 2.5.1.). Furthermore, after
intermittent morphine administration or sufficiently long chronic morphine treatment
and withdrawal, mice are sensitized to the acute morphine-induced hyperlocomotion
although there is tolerance towards this effect after a short withdrawal period (section
2.6.2.). In the experiments of Kuribara (1995), co-administration of D1- and D2-
receptor antagonists SCH 23390 and YM-09151-2, respectively, with intermittent
morphine administration reduced the locomotor sensitization to morphine; it was
suggested that changes in the cerebral dopaminergic neurotransmission are responsible
for the induction of locomotor sensitization to morphine in mice. The studies
mentioned in this section suggest that while there are certain differences in the effects
of acute morphine administration on the cerebral DA turnover and release and
locomotor activity in mice and rats, the behavioural sensitization in mice may show
similar temporal characteristics with cerebral DA release as those found in rats.
However, as in rats (Pert and Sivit 1977; Kalivas et al. 1983), part of the morphine-
induced locomotor hyperactivity of mice may be DA independent, or it may be
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regulated by cerebral dopaminergic systems and by other mechanisms.
2.8.2. Locomotor activity, opioid receptors and cerebral dopamine
The differences in the sensitivity to the behavioural effects of morphine in various
mouse strains have been suggested to be due to the differences in opioid receptor
subtypes and their distribution in the brain (Oliverio et al. 1983; Noble and Cox 1996).
In an early study using [3H]enkephalins, [3H]naloxone and [3H]dihydromorphine as
ligands, Reggiani et al. (1980) found that in DBA mice, in which acute morphine did
not increase the striatal or limbic DOPAC and HVA concentrations, the number of
striatal opioid binding sites was smaller than in C57BL mice; acute morphine increases
the locomotor activity of C57BL mice but not of DBA mice (Table 2-1). However, in a
study in which acute morphine increased the locomotor activity in one group of Swiss
mice and decreased it in another group, no differences were found in the number or
affinity of cerebral µ- or δ-receptors between mice belonging to either group
(Michaluk et al. 1991). Furthermore, in the experiments of Marona-Lewicka and
Vetulani (1989), acute morphine differentially altered the locomotor activity of C57BL
and Balb mice (Table 2-1) but no differences in the number or affinity of cerebral µ- or
δ-receptors between these mouse strains were found.
In ddY mice, ß-funaltrexamine, a µ1/µ2-receptor antagonist, abolished the acute
morphine-induced increase in the limbic DOPAC and HVA concentrations, as well as
locomotor hyperactivity (Narita et al. 1992; Suzuki et al. 1992a; Narita et al. 1993;
Funada et al. 1993b) emphasizing the role of activation of mesolimbic dopaminergic
transmission through an agonistic action on µ-receptors in the expression of morphine-
induced hyperlocomotion. Naloxone, a relatively selective µ-receptor antagonis, when
administered intermittently with morphine to dd mice, reduced the intermittent
morphine administration-induced locomotor sensitization suggesting the role of µ-
receptors in the induction of locomotor sensitization to morphine in mice (Kuribara
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1995). Furthermore, in addition to ß-funaltrexamine, the acute morphine-induced
locomotor hyperactivity, as well as increase in limbic DOPAC and HVA
concentrations, were reduced in ddY mice by pretreatment with pertussis toxin; thus,
the pertussis toxin sensitive Gi-protein mechanism may also play an important role in
the morphine-induced activation of mesolimbic DA transmission via µ-receptors and
in the consequent hyperlocomotion in mice (Funada et al. 1993b).
The acute morphine-induced locomotor hyperactivity and an increase in DOPAC and
HVA concentrations in the whole brain, limbic areas or striatum of ddY or ICR mice
can be reduced or abolished by κ-receptor agonists U-50488H (Narita et al. 1990,
1992, 1993; Suzuki et al. 1992b) or spiradoline (Kunihara et al. 1993). Furthermore,
norbinaltorphimine, a κ-receptor antagonist, increases the locomotor activity as well as
counteracts the reducing effect of the κ-receptor agonist U-50488H on the morphine-
induced increase of DOPAC and HVA concentrations in limbic areas of ddY mice
(Narita et al. 1992). κ-Receptor activation may thus inhibit the acute morphine-induced
activation of striatal or mesolimbic dopaminergic pathways, as well as locomotor
hyperactivity brought about by µ-receptor activation, and the effects of µ- and κ-
receptor agonists on DA-related actions such as motor activity and reinforcement in
mice may be opposite (Narita et al. 1990, 1992; Kunihara et al. 1993). This is in
agreement with previous rat studies as it has been suggested that in rats the positive
reinforcing effects of opioids are not mediated via κ-receptors (Shippenberg et al.
1993).
These studies, using various opioid receptor agonists and antagonists, give further
evidence that the activation of striatal and limbic dopaminergic systems by µ-receptors
is related to the morphine-induced increase in locomotor activity, at least in ddY and
ICR mice in which acute morphine increases the locomotor activity, whereas the
inhibition of these systems may decrease the activity.
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2.8.3. Locomotor activity and cerebral noradrenaline
In addition to the cerebral dopaminergic systems, the noradrenergic ones have been
suggested to be of importance in the morphine-induced changes in locomotor activity
in mice (Estler 1973; Kempf et al. 1976; Bläsig and Herz 1980; Michaluk et al. 1991).
Furthermore, in rats DA-induced locomotor behaviours are differentially (in opposite
directions) influenced by α1- and α2-adrenoceptor antagonists and it has been
suggested that NA may thus modulate the expression and character of behaviour so
that there is a regulatory role for NA in which locomotor behaviours are facilitated by
increased NA functional activity and inhibited by decreased NA activity (Dickinson et
al. 1988). However, due to the non-specificity of available agents the precise role of
the noradrenergic systems in mediating the morphine-induced changes in locomotor
activity is still largely undefined.  
Although there are several studies on the effects of various α1- and α2-adrenoceptor
agonists and antagonists on the spontaneous locomotor activity of mice and rats, only a
few experiments have been conducted to elucidate the effects of compounds which
manipulate the function of cerebral noradrenergic systems on the morphine-induced
hyperlocomotion in mice. It is considered that the acute morphine-induced locomotor
hyperactivity can be blocked in mice by substances selectively blocking noradrenergic
activity (Bläsig and Herz 1980). As summarised in Table 2-2, the acute morphine-
induced locomotor hyperactivity can be blocked or reduced in mice by various
nonselective α-adrenoceptor antagonists, as well as by compounds which reduce the
function of the noradrenergic systems. Furthermore, in the experiments of Michaluk et al.
(1991), in which acute morphine increased the locomotor activity in one group of Swiss
mice and decreased that in another group, between the two mouse groups no differences
were found in the binding parameters of cerebral opioid receptors, but in the group in
which morphine reduced the locomotor activity the number of cerebral α1-adrenoceptors
was smaller. Moreover, in an experiment in which morphine induced locomotor
hyperactivity in C57BL mice but not in Balb mice (Marona-Lewicka and Vetulani 1989),
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Table 2-2. Effect of various nonselective α-adrenoceptor antagonists (phentolamine, phenoxybenzamine,
tolazoline), of ß-adrenoceptor antagonist propranolol, of α- and ß-adrenoceptor antagonist aceperone, of
α2-adrenoceptor agonist clonidine as well of diethyldithiocarbamate, an inhibitor of NA biosynthesis
from DA by dopamine-ß-hydroxylase, on the acute morphine-induced locomotor hyperactivity in various
mouse strains.
Mouse Morphine dose Compound Effect Reference
strain Test period1 Time of administration
                                                                                                                                                        
Swiss 25 mg/kg2 i.p. Phentolamine 10 mg/kg i.p. ↓ Carroll and Sharp 1972
0-2 h 30 min before morphine
Swiss 25 mg/kg i.p. Phenoxybenzamine 10 mg/kg i.p. ↓ Carroll and Sharp 1972
0-2h 30 min before morphine
NMRI 5-15 mg/kg s.c. Phenoxybenzamine 50 mg/kg i.p. ↓ Estler 1973
0-2 h Immediately before morphine
NMRI 5-15 mg/kg s.c. Propranolol 5 or 20 mg/kg i.p. ± Estler 1973
0-2h Immediately before morphine
Swiss 20 mg/kg i.p. Diethyldithiocarbamate ↓↓ Kuschinsky and
40-45 or 50 min 500 mg/kg i.p. Hornykiewicz 1974
80 min before morphine
CF-1 100 mg/kg s.c. Phenoxybenzamine 5 mg/kg i.p. ↓ VanderWende et al.
 40-45 min 30 min before morphine 1975
CF-1 100 mg/kg s.c. Tolazoline 30 mg/kg i.p. ± VanderWende et al.
40-45 min 30 min before morphine 1975
3 100 mg/kg Phenoxybenzamine 10 mg/kg ↓ * Ayhan 1978
0-60 min 150 min before morphine
3 100 mg/kg Aceperone 10 mg/kg ↓ * Ayhan 1978
0-60 min 30 min before morphine
C57BL 10 & 20 mg/kg i.p. Clonidine 0.25 or 0.5 mg/kg i.p. ↓ Filibeck et al. 1980
15-65 min 45 min before morphine
                                                                                                                                                        
↓↓ blockade of acute morphine-induced locomotor hyperactivity, ↓ reduction of acute morphine-induced
locomotor hyperactivity, ± no effect on acute morphine-induced locomotor hyperactivity, *catalepsy.
1After acute morphine administration. 2After initial decrease in locomotor activity (0-15 min) acute
morphine induced locomotor hyperactivity (15 min-2 h). 3Mouse strain or route of administration not
given.
the morphine-induced accumulation of inositol trisphosphate in brain slices of C57BL
mice exceeded that in slices of Balb mice. It was hypothetised that the differences in
the morphine-induced locomotor activity may be due to the differences in the signal
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transduction mechanism of the cerebral α-adrenergic systems.
However, dihydroxyphenylserine, a direct precursor of NA in the brain, had no effect
on morphine-induced locomotor activity in CF-1 mice (VanderWende et al. 1975) and
there are no studies indicating enhancement of the morphine-induced locomotor
hyperactivity by α-adrenergic agonists in mice. Furthermore, unlike concerning DA,
there is no evidence of sensitization to the acute morphine-induced increase in NA
turnover and release after chronic morphine treatment and withdrawal. Moreover, in
rats the role of cerebral α1-adrenergic signal transduction systems or the activity of
locus coeruleus neurons in the behavioural sensitization, induced by chronic
administration of central stimulants such as cocaine or amphetamine, is not clear
(Harris and Williams 1992; Javaid et al. 1994).
It was suggested by Ayhan (1978) that the acute morphine-induced changes in
locomotor activity in mice could be regulated by both cerebral dopaminergic and
noradrenergic systems. However, the role of these systems could differ in mice and
rats in that the acute morphine-induced stimulation of cerebral noradrenergic systems
could be more pronounced in mice than in rats and could account for the morphine-
induced locomotor hyperactivity in mice. When the noradrenergic component is
blocked, morphine may produce a similar locomotor response in mice as in rats, which
could be mediated by the cerebral dopaminergic systems. The suggestion on the role of
several mechanisms involved in the mediation of morphine-induced alterations in
motor activity in mice is supported by VanderWende and Spoerlein (1979). They
suggested that in mice the acute morphine-induced locomotor hyperactivity
overshadows the decrease in activity;  drugs altering the balance between the various
regulatory systems would cause the alteration of the locomotor activity. In addition to
the dopaminergic and noradrenergic systems, other cerebral mechanisms, such as
serotonergic, GABAergic and histaminergic, may contribute to the regulation of the
morphine-induced changes in locomotor activity in mice (Svensson and Waldeck
1970; Fennessy and Lee 1972; Carroll and Sharp 1972; Biswas and Carlsson 1978;
48
VanderWende and Spoerlein 1979; Muley et al. 1982; Mickley 1986; Sansone et al.
1986; Suzuki et al. 1992b).
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3. AIMS OF THE STUDY
The aim of this work was to study the role of striatal dopaminergic and cerebral
noradrenergic systems in the morphine-induced behavioural sensitization in mice. This
was studied by elucidating the temporal coupling of the effects of morphine
withdrawal and challenge dose on striatal DA and cerebral NA turnover and release, as
well as on locomotor activity.
The specific aims were:
To investigate the effects of repeated morphine treatment and withdrawal on striatal
DA turnover and release. Furthermore, in order to study if the response of striatal
dopaminergic systems to a morphine challenge dose during the withdrawal is related to
the changes in the affinity or number of striatal DA receptors, the striatal binding of
D1- and D2-receptor ligands was measured.
To investigate the effects of repeated morphine treatment and withdrawal on cerebral
NA turnover and release in three brain areas: the forebrain-midbrain including the
cortical areas, the hypothalamus and the lower brain stem.
To investigate the effects of repeated morphine treatment and withdrawal on acute
morphine-induced locomotor hyperactivity. The time course of morphine-induced
behavioural sensitisation in mice was elucidated as well.
To study the role of cerebral noradrenergic systems in the expression of locomotor
sensitisation by estimating the effects of α2-adrenoceptor antagonist idazoxan
pretreatment on morphine-induced locomotor hyperactivity as well as on striatal DA
and cerebral NA turnover and release during morphine withdrawal.
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4. MATERIALS AND METHODS
4.1. Animals
Male NMRI mice, weighing 21-32 g at the beginning of the experiments were used
throughout the experiments. The animals were housed 6-10 in a home cage at an
ambient temperature of 21-23°C under 12 h dark-light cycle (lights on at 06:00). The
mice had free access to fresh tap water and standard pellet food. They were weighed
daily at 13:00-14:00 (I, II) or at 08:00-09:00 (III, IV). The weights of the mice at the
beginning of the repeated treatment, and the weight changes during the repeated
treatment and after withdrawal periods, have been given in studies I-IV. The same
mice were used in studies I and II when estimating the concentrations of DA, NA and
their metabolites. The experimental set-ups were approved by the Committee for
Animal Experiments of the Faculty of Science of the University of Helsinki.
4.2. Treatment
During the repeated treatments (Ahtee et al. 1987), the mice were given morphine s.c.
3 times daily, at 08:00-09:00, 14:00-15:00 and 22:00-23:00, for 5 days. The dose of
morphine was increased from 100 mg/kg x 3 on day 1 to 150 mg/kg x 3 on day 2, and
to 200 mg/kg x 3 on days 3-5. On day 5 the third daily morphine dose was omitted.
The control mice were given similar volumes of 0.9% NaCl solution (saline) s.c. In
studies I and II the acute treatments (αMT, morphine, saline) were given after
withdrawal periods of 1, 2 or 3 days, at 10:00-14:00, and in the biochemical
experiments the mice were decapitated at 12:00-16:00. In study III, the acute
treatments (morphine and saline) were given during the behavioural and biochemical
experiments after withdrawal periods of 1, 3 or 5 days at 11:00-14:00, and in the
biochemical experiments the mice were decapitated at 12:00-15:00. In study IV, the
acute treatments (idazoxan, morphine and saline) were given both during the
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behavioural and biochemical experiments after a withdrawal period of 3 days at 10:30-
13:30 and in the biochemical experiments the mice were decapitated at 12:00-15:00.
The dose of acute morphine was 10 mg/kg s.c. (I-IV) or 30 mg/kg s.c. (I, II), the dose
of αMT, 250 mg/kg i.p. (I, II) and that of idazoxan, 1 and 3 mg/kg i.p. (IV). In the
αMT-depletion experiments (I, II), acute morphine was administered 2.5 h before
decapitation and αMT 2 h before decapitation. In the metabolite experiments acute
morphine was administered 1 h (I, III, IV) or 2 h (II) before decapitation. Idazoxan was
administered 0.5 h before acute morphine (IV). In preliminary experiments using 0.3-
10 mg/kg of idazoxan, doses smaller than 10 mg/kg did not significantly alter the acute
morphine-induced locomotor hyperactivity in control mice. Thus, the idazoxan doses 1
and 3 mg/kg were used in the experiments. Furthermore, based on the preliminary
experiments studying the onset and duration of the effect of idazoxan on the locomotor
activity, idazoxan was administered 0.5 h before acute morphine.
4.3. Brain dissection
After decapitation the brains were rapidly excised and dissected on an ice-cooled glass
plate into 4 parts: 1) striatum, 2) hypothalamus, 3) lower brain stem, and 4) an area
designated "rest of forebrain + midbrain", consisting mainly of cortical areas,
hippocampus and thalamus, as described by Attila et al. (1987). In the experiments of
study II in which the free MOPEG concentration was estimated the limbic forebrain
was dissected from the brain area "rest of forebrain + midbrain", before dissecting the
hypothalamus. This was done from the ventral surface by lateral curved cuts
approximately at a depth of 2 mm from the bulbus olfactorius to the hypothalamus,
being careful no parts of the hypothalamus or caudate putamen were included. The
brain parts were frozen on dry ice immediately after dissection, and weighed, and
stored at -80°C until the concentrations of NA, DA or their metabolites could be
estimated or striatal binding studies could be done.
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4.4. Drugs
Morphine HCl (Ph. Eur., 2nd ed.) and idazoxan HCl (RBI, Natick, MA, USA) were
dissolved in saline and administered in a volume of 0.1 ml/10 g. α-Methyl-p-tyrosine
methylester HCl (αMT) (Labkemi, Stockholm, Sweden) was dissolved in distilled
water and administered in a volume of 0.2 ml/10 g. 3H-SCH 23390 was obtained from
Amersham (Buckinghamshire, UK), 3H-spiperone from New England Nuclear
(Dreieih, Germany) and (+)-butaclamol from Research Biochemicals International
(Natick, MA, USA). Cis(Z)-flupentixol was donated by H. Lundbeck A/S
(Copenhagen, Denmark) and ketanserin from Janssen Pharmaceutica (Beerse,
Belgium).
4.5. Analytical methods
4.5.1. Estimation of concentrations of dopamine, noradrenaline and their
metabolites (I-IV)
To estimate the dopaminergic and noradrenergic neuronal activity, the concentrations
of DA and its metabolites DOPAC, 3-MT and HVA, as well as NA and its metabolite
free MOPEG, were measured by using high performance liquid chromatography with
electrochemical detection methods. The method used in the αMT-depletion
experiments (I, II) is described by Attila and Ahtee (1984a). In this method the tissue
samples were purified using activated alumina. The catecholamines from the samples
were then extracted into perchloric acid and injected onto a chromatographic column
packed with strong cation exchange resin. DA and NA were detected using an
electrochemical detector constructed from commercial components. In another
method, used in the metabolite experiments (I-IV) and described by Haikala (1987),
the proteins from the tissue samples were precipitated by perchloric acid. The samples
were then purified and isolated using Sephadex G-10 gel chromatography. The
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fractions from the Sephadex G-10 eluates were injected into C18 reversed phase
chromatographic columns for estimation of DA, NA and their metabolites. In this
method, the detector consisted of an amperometric rotating-disc working electrode
(Haikala 1987); in some of the experiments an ESA Coulochem model 5100 or model
II detector was used. The contents of NA and DA in the tissue samples were about
similar regardless of the method used.
4.5.2. Dopamine D1- and D2-receptor binding assay (I)
The striata of 8-10 mice were pooled for each binding assay. The striata were
homogenized in ice-cold Tris-buffer. The homogenate was centrifuged and
rehomogenized in the buffer. The suspension obtained was used for both D1- and D2-
receptor subtype assays. The protein content of the homogenate was determined with a
modified Lowry method as described by Bailey (1967) using human albumin as a
standard. The tissue homogenate was pipetted into tubes containing Tris-buffer and
non-specific ligand, and pre-incubated at 37°C for 15 min in order to hydrolyse
endogenous DA. After this, radioligand (3H-SCH 23390 for the D1-receptor assay or
3H-spiperone for the D2-receptor assay) was added and the samples were incubated at
37°C for 20 min (D2-receptor assay) or for 30 min (D1-receptor assay). The incubation
was terminated by vacuum filtration by a Brandel Cell Harvester. The filters were
placed in vials with scintillation liquid, and the radioactivity of the samples was
measured by liquid scintillation counting. In parallel experiments, the incubation was
performed in the presence of non-specific ligands (1 µM cis(Z)-flupentixol for the D1-
receptor assay or 1 µM (+)-butaclamol for the D2-receptor assay). The specific binding
of radioligands was calculated by subtracting from the total binding the values for
nonspecific binding in the presence of non-specific ligands. Ketanserin was used in
D2-receptor binding experiments to prevent the binding of 3H-spiperone to 5-HT2-
receptors. All assays were done in triplicate or quadruplicate. The binding parameters
(Bmax and KD) were estimated by the method of Scatchard (1949).
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4.6. Estimation of locomotor activity (II-IV)
The mice were placed in groups of three in activity cages 18 x 33 x 15 cm. These
groups of three were taken from the same home cage in order not to affect the social
behaviour of the mice. The interruptions of photocell beams (40 photocells per cage)
were registered by a computerized counter. Locomotor activity was measured
immediately after morphine or saline administration at 5 min intervals for 2 h between
10:00-17:00. Each mouse was used only once. The magnitude and duration of the
exploration phase, when compared with the onset and magnitude of the effect of acute
morphine, was small (II). Therefore, mice were not habituated before the
measurement.
4.7. Statistical analysis
A two-tailed Student's t-test was used when comparing the means of body weight
changes (I-IV) or binding parameters (I).
In the locomotor activity experiments, ANOVA with repeated measures was used (II-
IV). In addition, 2-way ANOVA was used to estimate the effects of acute and repeated
treatment (2 x 2 groups) and of acute x repeated treatment interaction, at each 15 min
separately. When significant main effects (of acute or repeated treatment) were found,
comparisons of the group means at each point were performed using the Student's t-
test with pooled variance (III). In study IV, 2-way ANOVA was used to estimate the
effects of acute and repeated treatment (6 x 2 groups) and of acute x repeated treatment
interaction, at each 15 min separately. When significant main effects (of acute or
repeated treatment) were found, comparisons of the group means at each point were
performed using the Student-Newman-Keuls multiple range test. In addition, to
estimate the effects of acute and repeated saline and morphine treatment and their
interaction only (2 x 2 groups) in study IV, 2-way ANOVA was performed at each 15
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min separately.
In the DA and NA metabolite experiments, logarithmic transformation of data was
used when a significant correlation was found between group means and respective
standard deviations (I, II). In the αMT experiments, 3-way ANOVA (acute x repeated
treatment x withdrawal) was used. However, as 2-way ANOVA (acute x repeated
treatment) at each withdrawal period revealed no significant interactions and as none
of the withdrawal interactions with other factors were significant the effects of acute
and repeated treatment on the DA and NA concentrations were analysed separately at
each withdrawal period by 2-way ANOVA followed by the Student's t-test with pooled
variance (I, II). One-way ANOVA followed by the Student's t-test with pooled
variance was used when comparing the means of DA concentrations of pooled data of
1, 2 and 3 withdrawal days in control mice (I). In the DA and NA metabolite
experiments, the data were analysed separately at each withdrawal period. To estimate
the effects of acute and repeated treatment and their interaction (2 x 2 groups in studies
I-III, 6 x 2 groups in study IV) 2-way ANOVA was used. To estimate the effect of
acute and repeated saline and morphine treatment and their interaction only (2 x 2
groups) in study IV 2-way ANOVA was used. When significant main effects (of acute
or repeated treatment) were found, the comparisons of group means were performed
using Student's t-test with pooled variance. When significant acute x repeated
treatment interaction was found, planned contrasts were used to compare the effects of
acute or repeated treatment (II). P-values lower than 0.05 were considered to be
significant.
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5. RESULTS
5.1. Body weight during treatment and withdrawal (I-IV)
During the 5-day repeated treatment, the control mice given 3 daily saline injections
gained weight (2.6-3.6 g; mean weight change per group, see studies I-IV), whereas
the mice repeatedly given morphine lost weight (2.8-3.2 g). During the first with-
drawal day the control mice continued to gain weight (0.5-0.6 g) while the morphine-
withdrawn mice lost weight (0.2-1.0 g). After longer withdrawal periods (2 to 5 days)
the control mice continued to gain weight (0.1-0.9 g/day). During this period the
morphine-withdrawn mice gained more weight (0.7-1.7 g/day) than the corresponding
control mice. Thus, the morphine administration schedule used in these experiments
induced weight loss on the first day of withdrawal. This agrees with similar
experiments with rats (Akera and Brody 1968; Attila and Ahtee 1983). As the
withdrawal-induced weight loss is considered a reliable index of the magnitude of
physical dependence (Akera and Brody 1968; Stolerman et al. 1975), it is evident that
the morphine administration used in the present experiments induced physical
dependence in the mice treated repeatedly with morphine.
5.2. Striatal dopamine
5.2.1. Effect of morphine withdrawal on striatal dopamine metabolism (I, III, IV)
The αMT-induced depletion of striatal DA was retarded in mice withdrawn for 1 day
but no longer in mice withdrawn for 2 or 3 days from the 5-day repeated morphine
treatment (I). The striatal DA concentrations of mice withdrawn for 1, 3 or 5 days from
the repeated morphine treatment were not altered. The effects of 1, 3 and 5-day
withdrawal from the repeated morphine treatment on the striatal DOPAC, 3-MT and
HVA concentrations are summarised in Fig. 5-1. In mice withdrawn for 1 day from the
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Fig. 5-1. Effect of acute morphine challenge dose on striatal DOPAC, 3-MT and HVA concentrations
in mice withdrawn for 1, 3 or 5 days from the 5-day repeated morphine treatment. The acute morphine
challenge dose (30 mg/kg at 1-day withdrawal, 10 mg/kg at 3 and 5-day withdrawal) was given s.c. 1h
before decapitation. Figure summarises data from Study I (1-day withdrawal), Study IV (3-day
withdrawal) and Study III (5-day withdrawal). Statistical significances for the effect of acute
morphine treatment: *P<0.05, **P<0.01 and ***P<0.001, as compared with corresponding group
given saline acutely (B vs. A or D vs. C), and for the effect of repeated morphine treatment: ooP<0.01
and oooP<0.001, as compared with corresponding group given saline repeatedly (C vs. A or D vs. B),
and for the acute x repeated treatment interaction #P<0.05, ##P<0.01, ###P<0.001 (2-way ANOVA
followed by Student's t-test).
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repeated morphine treatment the striatal DOPAC and HVA concentrations were
decreased, while the striatal 3-MT concentration was not altered. In mice withdrawn
for 3 or 5 days from the repeated morphine treatment, the striatal DOPAC, HVA or 3-
MT concentrations were not altered.
5.2.2. Effect of morphine withdrawal on striatal dopamine receptors (I)
In mice withdrawn from the repeated morphine treatment for 1 day, the density of
striatal D1- or D2-receptors (Bmax) was not altered. However, in mice withdrawn for 3
days from the repeated morphine treatment, the density of striatal D2-receptors (Bmax)
was decreased, while that of striatal D1-receptors was not altered. In mice withdrawn
from the repeated morphine treatment for 1 or 3, days the affinity of striatal D1- or D2-
receptors (Kd) was not altered as compared with control mice.
5.2.3. Effect of acute morphine challenge on striatal dopamine metabolism (I, III,
IV)
In the control mice the acute morphine challenge doses 10 or 30 mg/kg did not alter
the striatal DA concentration while the 10 mg/kg but not the 30 mg/kg morphine
challenge dose enhanced the αMT-induced DA depletion (I). In the control mice the
10 and 30 mg/kg morphine challenge doses increased the striatal DOPAC and HVA
concentrations dose-dependently. However, both morphine challenge doses decreased
or tended to decrease the striatal 3-MT concentration (I; Fig. 5-1).
In mice withdrawn from the repeated morphine treatment for 1 to 5 days the acute
morphine challenge doses 10 or 30 mg/kg did not alter the striatal DA concentrations. 
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In mice withdrawn for 1 day from the repeated morphine treatment, the 10 and 30
mg/kg morphine challenge doses accelerated the αMT-induced DA depletion.
However, the striatal DA concentration of the morphine-withdrawn mice challenged
with 10 mg/kg of morphine was larger than that of the corresponding control mice (I).
Furthermore, in mice withdrawn from the repeated morphine treatment for 1 day, the
striatal DOPAC and HVA concentrations were increased by the 30 mg/kg morphine
challenge dose but the concentrations remained smaller than in corresponding control
mice (Fig. 5-1). The striatal 3-MT concentration was not altered by the morphine
challenge dose in mice withdrawn for 1 day from the repeated morphine treatment
(Fig. 5-1).
In mice withdrawn for 3 days from the repeated morphine treatment, the 10 mg/kg
morphine challenge dose increased the striatal HVA concentration to a greater extent
(I) or about similarly (III, IV) as in control mice; the striatal DOPAC concentration
was increased about similarly as in controls (I, Fig. 5-1). Furthermore, unlike in mice
withdrawn from the repeated morphine treatment for 1 day, at 3-day withdrawal, the
αMT-induced DA depletion was increased by the 10 mg/kg morphine challenge dose
to about same level as in corresponding control mice (I). In contrast to control mice,
the 10 mg/kg morphine challenge dose did not alter the striatal 3-MT concentration in
mice withdrawn from the repeated morphine treatment for 3 days and thus the striatal
3-MT concentration was significantly larger in morphine-withdrawn mice challenged
acutely with morphine than in corresponding control mice (I, Fig. 5-1). As compared
with control mice, the 30 mg/kg morphine challenge dose increased the striatal HVA
concentration less and the striatal DOPAC concentration about similarly in mice
withdrawn from the repeated morphine treatment for 3 days as in the control mice.
Furthermore, this dose tended to decrease the striatal 3-MT concentration both in
control and morphine-withdrawn mice (I).
In mice withdrawn for 5 days from the repeated morphine treatment the 10 mg/kg
morphine challenge dose increased the striatal DOPAC and HVA concentrations; the
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striatal DOPAC concentration was increased in the morphine-withdrawn mice about
similarly as in the control mice, and the striatal HVA concentration to a greater extent
than in the control mice (Fig. 5-1). In contrast to control mice, morphine challenge
dose did not alter the striatal 3-MT concentration in mice withdrawn for 5 days from
the repeated morphine treatment, and the striatal 3-MT concentration was thus
significantly larger in morphine-withdrawn mice treated acutely with morphine than in
corresponding control mice (Fig. 5-1).
5.2.4. Effect of idazoxan pretreatment on morphine's effects on striatal dopamine
metabolism (IV)
In the control mice, 1 or 3 mg/kg of idazoxan alone did not alter the striatal DOPAC,
HVA or 3-MT concentrations. However, 3 mg/kg of idazoxan alone and in
combination with the 10 mg/kg morphine challenge dose increased the striatal DA
concentration. Furthermore, pretreatment with 3 mg/kg of idazoxan enhanced the
morphine challenge dose-induced increase of striatal DOPAC concentration (Table 5-
1). Pretreatment with 1 mg/kg of idazoxan abolished the morphine challenge-induced
elevation of striatal HVA concentration and the effect of the morphine challenge on
the striatal HVA concentration was not significant in mice pretreated with 3 mg/kg of
idazoxan. Moreover, pretreatment with 1 mg/kg of idazoxan abolished the morphine
challenge-induced decrease of striatal 3-MT concentration, while in mice pretreated
with with 3 mg/kg of idazoxan the morphine challenge slightly increased the striatal 3-
MT concentration (Table 5-1).
In mice withdrawn for 3 days from the repeated morphine treatment, 3 mg/kg of
idazoxan alone increased the striatal DA and DOPAC concentrations. However, the
striatal DA concentration was not increased when idazoxan was administered before
the morphine challenge dose. Furthermore, pretreatment with 1 or 3 mg/kg of idazoxan
did not significantly  alter the  morphine challenge-induced increase in striatal DOPAC
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Table 5-1. Effect of acute morphine challenge dose (10 mg/kg s.c., 1 h before decapitation) on striatal
DA, DOPAC, HVA and 3-MT concentrations in mice withdrawn for 3 days from the 5-day repeated
morphine treatment and pretreated acutely with idazoxan (1 or 3 mg/kg i.p., 30 min before acute
morphine challenge dose) or saline.
Acute morphine challenge-induced change                            
Repeated Pre- DA          DOPAC    HVA       3-MT         
treatment treatment
                                                                                                                                            
Saline Saline ± ↑ ↑ ↓↓↓
Saline Idazoxan 1 ± n.s. ↑↑↑ n.s. ± * ± ***
Saline Idazoxan 3 ↑↑↑ *** ↑↑↑ * ± n.s. ↑ ***
Morphine Saline ± ↑↑ ↑↑↑ ±
Morphine Idazoxan 1 ± n.s. ↑↑↑ n.s. ± * ± n.s.
Morphine Idazoxan 3 ± n.s. ↑↑↑ n.s. ± ** ↑ n.s.
                                                                                                                                            
The significant changes induced by the acute morphine challenge dose: ↑ increase of P<0.05, ↑↑ increase
of P<0.01, ↑↑↑/↓↓↓ increase/decrease of P<0.001, ± no significant morphine challenge-induced change.
The significant idazoxan pretreatment-induced changes on the effect of acute morphine challenge dose:
*P<0.05, **P<0.01, ***P<0.001, n.s. no significant idazoxan pretreatment-induced change. Table shows
data from study IV; the statistical significances between idazoxan pretreated mice challenged with
morphine and control mice were calculated from the results of Study IV (columns D vs. A or H vs. E in
Figs. 5 and 6 in Study IV).
concentration; thus, the striatal DOPAC concentration was increased by the morphine
challenge dose in morphine-withdrawn mice pretreated with idazoxan about similarly
as in controls (Table 5-1). Idazoxan (1 or 3 mg/kg) alone did not alter the striatal HVA
concentration in the morphine-withdrawn mice. However, idazoxan pretreatment
abolished the morphine challenge-induced increase of striatal HVA concentration in
the morphine-withdrawn mice (Table 5-1). Idazoxan alone did not alter the striatal 3-
MT concentration of morphine-withdrawn mice; however, similarly as in controls, the
morphine challenge slightly increased the striatal 3-MT concentration in morphine-
withdrawn mice pretreated with 3 mg/kg of idazoxan (Table 5-1).
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5.3. Cerebral noradrenaline
5.3.1. Effect of morphine withdrawal on cerebral noradrenaline metabolism (II-
IV)
"Rest of forebrain + midbrain". One day withdrawal from the repeated morphine
treatment did not alter or elevated the NA concentration but retarded the αMT-induced
NA depletion while the free MOPEG concentration was slightly increased. Three- or
5-day withdrawal from the repeated morphine treatment did not alter the NA or the
free MOPEG concentrations in this area. Neither was the αMT-induced NA depletion
altered in mice withdrawn for 3 days.
Hypothalamus. One or 3-day withdrawal from the repeated morphine treatment did not
alter the αMT-induced NA depletion in the hypothalamus. The NA concentration was
not altered after 1-, 3- or 5-day withdrawal except in study III in which the NA
concentration was increased at 3-day withdrawal. The free MOPEG concentrations
were not altered at 1,3 or 5-day withdrawal from the repeated morphine treatment.
Lower brain stem. One day withdrawal from the repeated morphine treatment did not
alter the NA concentration or the αMT-induced NA depletion but increased the free
MOPEG concentration. Three day withdrawal from the repeated morphine treatment
did not alter the NA concentration, the αMT-induced NA depletion or the free
MOPEG concentration. The NA or free MOPEG concentrations were not altered after
5-day withdrawal.
5.3.2. Effect of acute morphine challenge on cerebral noradrenaline metabolism
(II-IV)
"Rest of forebrain + midbrain". In the control mice the acute morphine challenge
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doses 10 and 30 mg/kg accelerated the αMT-induced NA depletion (II). Both
morphine challenge doses also increased the free MOPEG concentration. However,
the NA concentration of the control mice was not altered by either acute morphine
challenge dose (Table 5-2).
In mice withdrawn for 1 day from the repeated morphine treatment, the 10 or 30 mg/kg
morphine challenge doses did not alter the αMT-induced NA depletion at all (II); the
30 mg/kg morphine challenge dose did not alter the free MOPEG or NA
concentrations either (Table 5-2).
In mice withdrawn for 3 days, only the larger 30 mg/kg morphine challenge dose
accelerated the αMT-induced NA depletion but its effect was smaller than in the
corresponding control mice. Thus, the NA concentration of the morphine-withdrawn
mice given acutely 30 mg/kg of morphine was larger than in corresponding control
mice (II). Furthermore, the 10 mg/kg morphine challenge dose increased the free
MOPEG concentration in the morphine-withdrawn mice significantly less than in the
control mice, and the free MOPEG concentration was thus smaller in the morphine-
withdrawn mice challenged acutely with morphine than in corresponding control mice
(III, IV). The NA concentration was not altered by the acute morphine challenge dose
(Table 5-2).
In mice withdrawn for 5 days, the 10 mg/kg morphine challenge dose increased the
free MOPEG concentration. The increase was smaller than in the control mice (Table
5-2) but unlike at 1- or 3-day withdrawal, the free MOPEG concentration of the
morphine-withdrawn mice challenged acutely with morphine no longer differed
significantly from that of the control mice (III). The NA concentration was not altered
by the acute morphine challenge dose (Table 5-2).
Lower brain stem. In the control mice both the 10 and 30 mg/kg acute morphine
challenge doses accelerated the αMT-induced NA depletion (II) and increased the free
MOPEG concentration (Table 5-2). However, the NA concentration of the control
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mice was not altered by the acute morphine challenge doses (Table 5-2).
Table 5-2. Effect of acute morphine challenge dose on NA and free MOPEG concentrations in the area
"rest of forebrain + midbrain" (RFBR), lower brain stem (LBS) and hypothalamus (HYP) in mice
withdrawn for 1, 3 or 5 days from the 5-day repeated morphine treatment.
        RFBR                 LBS                    HYP             
Repeated NA  MOPEG NA   MOPEG NA MOPEG
treatment
                                                                                                                                         
1-day withdrawal
Saline ± ↑↑↑ ± ↑↑↑ ↓↓ ↑↑↑
Morphine ± ± ± ± ± ±
3-day withdrawal
Saline ± ↑↑↑ ± ↑↑↑ ± ↑↑↑
Morphine ± ↑ ± ↑↑ ± ±
5-day withdrawal
Saline ± ↑↑↑ ± ↑↑↑ ± ↑↑↑
Morphine ± ↑ ± ↑↑↑ ± ↑↑↑
                                                                                                                                          
Table summarises results from Fig. 4 in Study II (1-day withdrawal), Figs. 3 and 4 in Study IV (3-day
withdrawal) and Fig. 4 in Study III (5-day withdrawal). The significant changes induced by the acute
morphine challenge dose: ↑ increase of P<0.05, ↑↑/↓↓ increase/decrease of P<0.01, ↑↑↑ increase of
P<0.001, ± no significant morphine challenge-induced change. The acute morphine challenge dose at 1-
day withdrawal was 30 mg/kg s.c. (2 h before decapitation) and at 3- and 5-day withdrawal 10 mg/kg s.c.
(1 h before decapitation).
In mice withdrawn for 1 day from the repeated morphine treatment, the 10 and 30
mg/kg morphine challenge doses did not alter the αMT-induced NA depletion at all
(II); the 30 mg/kg morphine challenge dose did not alter the free MOPEG or NA
concentrations either (Table 5-2).
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In mice withdrawn for 3 days from the repeated morphine treatment, the morphine
challenge doses 10 or 30 mg/kg did not alter the αMT-induced NA depletion;
however, the NA concentrations of these morphine-withdrawn mice after treatment
with αMT no longer differed from those of corresponding control mice (II).
Furthermore, the 10 mg/kg morphine challenge dose increased the free MOPEG
concentration in the morphine-withdrawn mice significantly less than in the
corresponding control mice (III, IV). The 10 mg/kg morphine challenge dose did not
alter the NA concentration in the morphine-withdrawn mice (Table 5-2).
In mice withdrawn for 5 days from the repeated morphine treatment, the 10 mg/kg
morphine challenge dose increased the free MOPEG concentration to the same extent
as in the corresponding control mice and did not alter the NA concentration (Table 5-
2).
Hypothalamus. In the control mice the 30 mg/kg morphine challenge dose accelerated
the αMT-induced NA depletion (II) and both the 10 and 30 mg/kg morphine challenge
doses increased the free MOPEG concentration (Table 5-2). Furthermore, the 30
mg/kg morphine challenge dose decreased the NA concentration (Table 5-2).
In mice withdrawn for 1 day from the repeated morphine treatment, the 10 or 30 mg/kg
morphine challenge doses did not alter the αMT-induced NA depletion (II) or the free
MOPEG or NA concentrations at all (Table 5-2).
In mice withdrawn for 3 days from the repeated morphine treatment, the 10 and 30
mg/kg morphine challenge doses did not alter the αMT-induced NA depletion and the
NA concentrations of these morphine-withdrawn mice were larger than in
corresponding control mice (II). Furthermore, the acute 10 mg/kg morphine challenge
dose did not alter the free MOPEG concentration at all (IV) or increased it
significantly less than in control mice. Thus, the free MOPEG concentration was
smaller in the morphine-withdrawn mice challenged acutely with morphine than in
corresponding control mice (III). The NA concentration was not altered by the
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morphine challenge (Table 5-2).
In mice withdrawn for 5 days from the repeated morphine treatment the 10 mg/kg
morphine challenge dose did not alter the NA concentration but increased the free
MOPEG concentration (Table 5-2). However, the free MOPEG concentration still
remained smaller than in corresponding control mice (III).
5.3.3. Effect of idazoxan pretreatment on morphine's effects on cerebral
noradrenaline metabolism (IV)
"Rest of forebrain + midbrain". In the control mice 1 and 3 mg/kg of idazoxan alone
increased the NA concentration. However, when idazoxan was administered before the
morphine challenge dose, the NA concentration was not increased (Table 5-3).
Idazoxan alone did not alter the free MOPEG concentration in the control mice but
idazoxan pretreatment enhanced the morphine challenge-induced increase of free
MOPEG concentration (Table 5-3).
In mice withdrawn for 3 days from the repeated morphine treatment, 1 and 3 mg/kg of
idazoxan alone, as in control mice, increased the NA concentration; when idazoxan
was administered before the morphine challenge the NA concentration was not
increased (Table 5-3). In the morphine-withdrawn mice idazoxan alone, in contrast to
control mice, increased the free MOPEG concentration. The morphine challenge dose
alone increased the free MOPEG concentration in the morphine-withdrawn mice less
than in control mice but pretreatment with idazoxan enhanced the morphine challenge
dose-induced increase of free MOPEG concentration (Table 5-3) so that it was
increased to about same level as in control mice.
Lower brain stem. In the control mice, 1 or 3 mg/kg of idazoxan alone did not alter the
NA or free MOPEG concentrations.  The NA concentration  was decreased in idazoxan
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Table 5-3. Effect of acute morphine challenge dose (10 mg/kg s.c., 1 h before decapitation) on NA and
free MOPEG concentrations in the area "rest of forebrain + midbrain" (RFBR), lower brain stem (LBS)
and hypothalamus (HYP) in mice withdrawn for 3 days from the 5-day repeated morphine treatment and
pretreated acutely with idazoxan (1 or 3 mg/kg i.p., 30 min before acute morphine challenge dose) or
saline.
Acute morphine-induced change                 
Repeated Pre- NA            MOPEG      
treatment treatment
                                                                                                                            
RFBR
Saline Saline ± ↑↑↑
Saline Idazoxan 1 ± n.s. ↑↑↑ **
Saline Idazoxan 3 ± n.s. ↑↑↑ ***
Morphine Saline ± ↑
Morphine Idazoxan 1 ± n.s. ↑↑↑ ***
Morphine Idazoxan 3 ± n.s. ↑↑↑ ***
LBS
Saline Saline ± ↑↑↑
Saline Idazoxan 1 ↓↓  *** ↑↑↑ n.s.
Saline Idazoxan 3 ± * ↑↑↑ **
Morphine Saline ± ↑↑
Morphine Idazoxan 1 ± n.s. ↑↑↑ **
Morphine Idazoxan 3 ± n.s. ↑↑↑ ***
HYP
Saline Saline ± ↑↑↑
Saline Idazoxan 1 ± n.s. ↑↑↑ n.s.
Saline Idazoxan 3 ± n.s. ↑↑↑ n.s.
Morphine Saline ± ±
Morphine Idazoxan 1 ± n.s. ↑↑  n.s.
Morphine Idazoxan 3 ↓ * ↑↑↑ ***
                                                                                                                        
The significant changes induced by the acute morphine challenge dose: ↑/↓ increase/decrease of P<0.05,
↑↑/↓↓ increase/decrease of P<0.01, ↑↑↑ increase of P<0.001, ± no significant morphine challenge-
induced change. The significant idazoxan pretreatment-induced changes on the effect of acute morphine
challenge dose: *P<0.05, **P<0.01, ***P<0.001, n.s. no significant idazoxan pretreatment-induced
change. Table shows data from study IV; the statistical significances between idazoxan pretreated mice
challenged with morphine and control mice were calculated from the results of Study IV (columns D vs.
A or H vs. E in Figs. 3 and 4 in Study IV).
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1 mg/kg-pretreated mice given morphine acutely. Furthermore, pretreatment with 3
mg/kg of idazoxan enhanced the acute morphine challenge dose-induced increase of
free MOPEG concentration in the corresponding control mice (Table 5-3).
In mice withdrawn for 3 days from the repeated morphine treatment, idazoxan, the
morphine challenge, or both these combined, did not alter the NA concentrations
(Table 5-3). In the morphine-withdrawn mice 3 mg/kg of idazoxan alone, in contrast to
control mice, increased the free MOPEG concentration. The morphine challenge dose
alone increased the free MOPEG concentration in the morphine-withdrawn mice less
than in the control mice; however, pretreatment with idazoxan enhanced the morphine
challenge dose-induced increase of free MOPEG concentration (Table 5-3) so that it
was increased to about the same level as in corresponding control mice.
Hypothalamus. In the control mice 1 mg/kg but not 3 mg/kg of idazoxan increased the
NA concentration. However, when idazoxan was administered in combination with
morphine the NA concentration was not altered. Idazoxan alone did not alter the free
MOPEG concentration or modify acute morphine's effect on that in the control mice
(Table 5-3).
In mice withdrawn for 3 days from the repeated morphine treatment, 1 or 3 mg/kg of
idazoxan alone did not alter the NA or free MOPEG concentrations. However, when 3
mg/kg of idazoxan was administered in combination with morphine, the NA
concentration was decreased (Table 5-3). The morphine challenge dose alone did not
increase the free MOPEG concentration in the morphine-withdrawn mice; however, in
the morphine-withdrawn mice pretreated with idazoxan morphine challenge clearly
increased the free MOPEG concentration (Table 5-3) so that in mice pretreated with 3
mg/kg of idazoxan it was increased to about the same level as in corresponding control
mice.
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5.4. Locomotor activity
5.4.1. Effect of morphine withdrawal on locomotor activity (III, IV)
In mice withdrawn for 1 day from the repeated morphine treatment, the locomotor
activity was slightly decreased (III). However, in mice withdrawn for 3 or 5 days from
the repeated morphine treatment the locomotor activity was not altered.
5.4.2. Effect of acute morphine challenge on locomotor activity (II-IV)
In the control mice the acute morphine challenge doses 10 and 30 mg/kg clearly
increased the locomotor activity (II-IV).
In mice withdrawn for 1 day from the repeated morphine treatment, the 10 mg/kg
morphine challenge dose did not alter the locomotor activity at all (Fig. 5-2).
In mice withdrawn for 3 days from the repeated morphine treatment, the 10 mg/kg
morphine challenge dose increased the locomotor activity about similarly as in
corresponding control mice treated repeatedly with saline (Fig. 5-2).
In mice withdrawn for 5 days from the repeated morphine treatment, the 10 mg/kg
morphine challenge dose increased the locomotor activity clearly more than in
corresponding control mice treated repeatedly with saline (Fig. 5-2).
5.4.3. Effect of idazoxan pretreatment on morphine's effect on locomotor activity
(IV)
In the control mice 1 or 3 mg/kg of idazoxan alone did not alter the locomotor activity.
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Fig. 5-2. Effect of acute morphine challenge dose (10 mg/kg s.c.) on the locomotor activity of mice
withdrawn for 1, 3 or 5 days from the 5-day repeated morphine treatment. The mice withdrawn for 3
days from the repeated morphine treatment were pretreated acutely with idazoxan (1 or 3 mg/kg) i.p.,
30 min before the morphine challenge dose. Figure summarises data (cumulative locomotor activity
counts at 120 min after acute morphine challenge dose) from Study III (1 and 5-day withdrawal) and
Study IV (3-day withdrawal). Statistical significances for the effect of acute morphine treatment:
*P<0.05, **P<0.01 and ***P<0.001, as compared with corresponding group given saline acutely (B
vs. A, F vs. E, D vs. C, H vs. G, D vs. A or H vs. E), for the effect of idazoxan pretreatment +P<0.05
and +++P<0.001, as compared with corresponding group given saline acutely (H vs. F), and for the
effect of repeated morphine treatment: oP<0.05 and oooP<0.001, as compared with corresponding
group given saline repeatedly (F vs. B or H vs. D) (Repeated measures ANOVA).
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Furthermore, pretreatment with idazoxan did not alter the morphine challenge-induced
locomotor hyperactivity in the control mice (Fig. 5-2).
In mice withdrawn from the repeated morphine treatment for 3 days, 1 or 3 mg/kg of
idazoxan alone did not alter the locomotor activity. However, pretreatment with 1 or 3
mg/kg of idazoxan clearly enhanced the morphine challenge dose-induced locomotor
hyperactivity in the morphine-withdrawn mice. Thus, the morphine challenge dose
increased the locomotor activity of morphine-withdrawn mice pretreated with
idazoxan to a greater extent than that of morphine-withdrawn mice pretreated with
saline. Furthermore, acute morphine challenge dose in combination with idazoxan
increased the locomotor activity of morphine-withdrawn mice to a greater extent than
that of corresponding control mice treated repeatedly with saline (Fig. 5-2).
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6. DISCUSSION
6.1. Striatal dopamine
6.1.1. Morphine withdrawal
The αMT-induced depletion of striatal DA was retarded and the striatal DOPAC and
HVA concentrations were decreased in mice withdrawn for 1 day, but no longer in
mice withdrawn for 3 days from the 5-day repeated morphine treatment. At 5-day
withdrawal from the repeated morphine treatment the concentrations of striatal DA or
its metabolites were not altered. Thus, 1-day withdrawal from the repeated morphine
treatment decreased the synthesis and release of DA, because the DA depletion after
blockade of the rate limiting enzyme in DA synthesis, tyrosine hydroxylase, by αMT
was retarded and because the concentrations of DOPAC (as an indicator of
intraneuronal DA synthesis and metabolism) and HVA (as an indicator of the sum of
DA metabolism and release) (section 2.3.1.) were decreased. The results agree with
studies in which withdrawal from chronic morphine treatment has been shown to
decrease the synthesis rate of DA in the mouse whole brain (Rosenman and Smith
1972) or to decrease the αMT-induced DA depletion or HVA concentration in
striatum of mice (De La Baume et al. 1979; Ahtee et al. 1987; Etemadzadeh 1993,
1994). DA turnover and release is decreased in striatum and in the limbic brain areas
also in rats on withdrawal from chronic morphine treatment (Ahtee 1973, 1974; Attila
and Ahtee 1983, 1984b; Ahtee et al. 1989; Acquas et al. 1991; Acquas and Di Chiara
1992; Wakabayashi et al. 1995). Thus, the present results give further evidence that,
similarly as in rats, the activity of dopaminergic neurons is attenuated in striata of mice
shortly after the withdrawal from repeated morphine treatment.
The retardation of DA synthesis and release coincided with the withdrawal-induced
loss of body weight which was observed at 1 day after withdrawal from the repeated
morphine treatment. The withdrawal-induced loss of body weight is also observed in
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rats at the time of retardation of DA turnover and release (Attila and Ahtee 1984a, b).
As the body weight loss is considered a reliable sign of opioid withdrawal in rats
(Stolerman et al. 1975), it is possible that the retardation may contribute to the
withdrawal signs.
6.1.2. Morphine challenge
At 1-day withdrawal from the repeated morphine treatment the morphine challenge
dose increased the striatal DOPAC and HVA concentrations. However, these
concentrations still remained smaller than in corresponding control mice. Furthermore,
unlike in the control mice morphine challenge dose did not alter the striatal 3-MT
concentration. The present results support the previous findings, which indicate that in
mice there is tolerance towards the striatal DA turnover and release enhancing effect of
acute morphine shortly after withdrawal (Fukui and Takagi 1972; Rosenman and
Smith 1972; Smith et al. 1972; Ahtee et al. 1987). However, in the present study acute
morphine clearly enhanced the αMT-induced DA depletion in striata of mice
withdrawn for 1 day, whereas in the striata of control mice acute morphine accelerated
the DA depletion only weakly. Thus, in mice withdrawn from the repeated morphine
treatment for 1 day, the morphine challenge dose partially counteracted the
withdrawal-induced reduction of striatal DA synthesis and release. At 3-day
withdrawal the αMT-induced DA depletion accelerating effect of the 10 mg/kg
morphine challenge dose was clearly enhanced. Furthermore, in contrast to mice
withdrawn from the repeated morphine treatment for 1 day, this dose elevated the
striatal DOPAC and HVA concentrations more clearly in mice withdrawn for 3 or 5
days than in control mice. Furthermore, the 10 mg/kg morphine challenge dose which
decreased the striatal 3-MT concentration in the corresponding control mice did not
alter the 3-MT concentration in mice withdrawn from morphine for 3 or 5 days. The
morphine-induced changes of striatal HVA, DOPAC and 3-MT concentrations, as well
as αMT-induced DA depletion, can be interpreted as an enhanced turnover and release
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of DA in mice withdrawn from the repeated morphine treatment for 3 or 5 days. Thus,
after repeated morphine treatment and sufficiently long withdrawal, mice were
sensitized to the DA turnover and release increasing effects of acute morphine. Similar
sensitization after repeated morphine treatment and withdrawal has been found in rats
(Attila and Ahtee 1983, 1984b; Ahtee et al. 1989, 1990; Acquas and Di Chiara 1992;
Spanagel and Shippenberg 1993; Honkanen et al. 1994).
Although the main effect of acute systemic morphine administration in mice is an
increase in cerebral DA turnover and release (Smith et al. 1970; Rethy et al. 1971;
Fukui and Takagi 1972; Rosenman and Smith 1972; Kuschinsky and Hornykiewicz
1974; Bloom et al. 1976; De La Baume et al. 1979; Reggiani et al. 1980; Wood et al.
1980; Wood and Richard 1982; Ishikawa et al. 1983; Nabeshima et al. 1985; Ahtee et
al. 1987; Attila et al. 1987; Saito 1990; Narita et al. 1992; Etemadzadeh 1993;
Kunihara et al. 1993; Funada et al. 1993b, 1994), acute morphine has also been
reported to decrease the striatal 3-MT concentration in mice (Racagni et al. 1979; Saito
1990). Using in vivo microdialysis it has been shown that in rats acute morphine when
administered locally inhibits the release of striatal DA (Rossetti et al. 1990; Piepponen
et al. 1999). Thus, morphine may have a dual effect on nigrostriatal DA release, a
stimulatory effect on the somatodendritic region of dopaminergic neurons and an
inhibitory effect on the terminal area of these neurons; tolerance develops more readily
to the inhibitory effect of morphine, which may contribute to the sensitization of DA
release in rats (Piepponen et al. 1999). Furthermore, the sensitization in morphine-
withdrawn mice could be explained by two separate mechanisms with different dose-
responses and tolerance development: a stimulatory one which may be activated by
small doses of morphine, and an inhibitory one activated by relatively large morphine
doses. Thus, the 10 mg/kg morphine dose used in the present experiments slightly
enhanced the striatal DA depletion in the control mice, but the larger 30 mg/kg dose
did not. This is in agreement with the experiments of Maissonneuve et al. (1991) who
in microdialysis studies found that 5 mg/kg but not 30 mg/kg of morphine increased
the extracellular DA concentration in rat striatum. The inhibitory mechanism may
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become more readily tolerant than the stimulatory one during repeated morphine
administration, shown in the present experiments by the sensitization of the αMT-
induced DA depletion increasing effect of only the 10 mg/kg dose of morphine. When
the stimulatory mechanism can work unopposed, morphine-induced DA release is
enhanced.
The reduced DA release during morphine withdrawal could lead to the development of
supersensitive postsynaptic D1 dopamine-receptors or to a reduced inhibition of DA
release via presynaptic D2 dopamine-receptors. Unlike in the rat study of Bhargava and
Gulati (1990) in the present study 1- or 3-day withdrawal from the morphine treatment
did not alter the striatal binding of D1-ligand 3H-SCH 23390. However, 3-day but not
1-day withdrawal from morphine slightly reduced the Bmax-value of striatal 3H-
spiperone binding suggesting reduced density of D2-receptors. This agrees with rat
studies of Puri et al. (1978). Although the density of D2-receptors has been found to be
increased in the brains of morphine-tolerant mice (Martin and Takemori 1986) and in
striata of morphine-tolerant rats (Carlson and Cooper 1985), the latter investigators
found a decrease in the number of striatal D2-receptors at 5 weeks after withdrawal
from chronic morphine administration. It is possible that also in mice D2-receptors are
up-regulated during chronic morphine treatment, return to control level during
withdrawal, and are down-regulated in protracted abstinence, as suggested by Carlson
and Cooper (1985) for rats. Such down-regulation could lead to decreased control of
DA release by autoreceptors and by those postsynaptic D2-receptors contributing to the
autoregulation via the long striatonigral feedback pathway (Kondo and Iwatsubo
1980). It is possible that the down-regulation of striatal D2-receptors found in the
present study could contribute to the enhanced DA release by the acute morphine
challenge dose during morphine withdrawal. Furthermore, it has been suggested that
the changes in D1- and D2-receptors during intermittent morphine administration in
mice may play an important role in the locomotor sensitization to morphine (Kuribara
1995).
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6.1.3. Idazoxan pretreatment
Idazoxan's effects on striatal DA metabolism were relatively small. At 3 mg/kg
idazoxan increased the striatal DA concentration both in the control and morphine-
withdrawn mice, elevated the striatal DOPAC concentration in the morphine-
withdrawn mice, as well as enhanced the acute morphine-induced increase in striatal
DOPAC concentration in the control but not in the morphine-withdrawn mice.
Furthermore, pretreatment with idazoxan abolished the acute morphine-induced
decrease of striatal 3-MT concentration in the control mice. These findings agree with
previous reports that in rats idazoxan when administered alone stimulates cerebral DA
metabolism and DA cell firing (Tian et al. 1991; Grenhoff and Svensson 1993;
Nisenbaum and Abercrombie 1993; Paez and Leibowitz 1993; Chen and Reith 1995).
In rats, the alteration of adrenergic tone from the locus coeruleus may result in an
alteration of the firing rate of mesolimbic and striatal DA neurons (Grenhoff and
Svensson 1993), or α2-adrenoceptors located on cerebral dopaminergic neurons may
exert a direct influence on mesolimbic and nigrostriatal dopaminergic neurons (Biegon
et al. 1992; Trendelenburg et al. 1994). α2-Adrenoceptors have been suggested to be
involved in the regulation of the dopaminergic neurons also in the mouse brain
(Sallinen et al. 1997; Yavich et al. 1997).
In the present study, in the control mice 1 mg/kg but not 3 mg/kg of idazoxan 
prevented the acute morphine-induced increase of striatal HVA concentration, and in
the morphine-withdrawn mice both these idazoxan doses prevented it. This effect of
idazoxan clearly differs from its effects on the striatal DOPAC and 3-MT
concentrations, and its mechanisms remain to be elucidated. In the morphine-
withdrawn mice, 1 mg/kg of idazoxan did not alter morphine's effect on the striatal 3-
MT concentration while 3 mg/kg of idazoxan evoked similar morphine-induced
increase in the striatal 3-MT concentration in the control and morphine-withdrawn
mice. As the concentrations of HVA and 3-MT are considered to indicate the release
of DA, the present findings show that although idazoxan altered the striatal DA
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metabolism both in the control and morphine-withdrawn mice, 1 mg/kg of idazoxan
did not evoke morphine-induced increase of striatal DA release in the morphine-
withdrawn mice at all, and the 3 mg/kg of idazoxan evoked morphine-induced
alteration of striatal DA release was similar in the morphine-withdrawn and control
mice. Thus, idazoxan pretreatment did not potentiate the effects of morphine challenge
dose on striatal DA release in the morphine-withdrawn mice.
6.2. Cerebral noradrenaline
6.2.1. Morphine withdrawal
One-day withdrawal from the repeated morphine treatment retarded the αMT-induced
NA depletion as well as tended to increase the NA concentration in the area "rest of
forebrain + midbrain", indicating reduced release of NA in this brain area. However,
the free MOPEG concentration was increased in the area "rest of forebrain +
midbrain" and in the lower brain stem, suggesting enhanced NA turnover. It is possible
that the αMT-induced NA depletion and the free MOPEG concentration are indicators
of different changes in NA turnover and release. In the hypothalamus of mice
withdrawn for 1 day from the repeated morphine treatment no changes were found.
Three- or 5-day withdrawal from the repeated morphine treatment did not alter the free
MOPEG concentrations in any brain area studied while the hypothalamic NA
concentration was increased after 3-day withdrawal but not any more after 5-day
withdrawal. It has been shown previously that shortly after the withdrawal from
chronic morphine treatment, the αMT-induced depletion of cerebral NA, or the
cortical MOPEG concentration are not altered and the synthesis of cerebral NA is even
retarded (Rosenman and Smith 1972; Smith et al. 1972; Etemadzadeh 1993, 1994;
Funada et al. 1993a). Thus, the present results suggest that in mice the withdrawal-
induced changes of cerebral NA turnover and release are modest and are observed only
shortly after the repeated morphine treatment.
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 Furthermore, the present results suggest that changes in the αMT-induced NA
depletion and in the free MOPEG concentration may indicate different changes in NA
turnover and release and that morphine withdrawal may induce dual effects on the
cerebral NA turnover and release in mice. The effects of chronic morphine treatment
and withdrawal in mice thus clearly differ from those in rats. In rats, the activity of
locus coeruleus neurons is increased during morphine withdrawal (Rasmussen et al.
1990) and morphine withdrawal accelerates the αMT-induced NA depletion, decreases
the NA concentration and increases the free or sulphated MOPEG concentrations in
most rat brain areas, including the lower brain stem, cortical areas and hypothalamus,
suggesting enhanced NA turnover and release (Gunne et al. 1969; Gramsch and Bläsig
1976; Crawley et al. 1979; Swann et al. 1983; Attila and Ahtee 1983, 1984a; Attila
1989; Ahtee et al. 1989). Thus, the modest withdrawal-induced changes found in mice
suggest that the noradrenergic mechanisms play a smaller role in mice than in rats
during stressful situations like morphine withdrawal. On the other hand, it has been
suggested that even in rats the hyperactivity of the locus coeruleus during morphine
withdrawal may result from an augmented excitatory amino-acid afferent input, as well
as from an increased basal firing rate of the locus coeruleus neurons (Akaoka and
Aston-Jones 1991; Kogan et al. 1992).
6.2.2. Morphine challenge
In the control mice, acute morphine increased the αMT-induced NA depletion and the
free MOPEG concentration in all brain areas studied, as well as slightly reduced the
hypothalamic NA concentration. This is in agreement with earlier studies indicating
that acute morphine increases NA synthesis, as well as increases αMT-induced NA
depletion, in the whole brain, hypothalamus, lower brain stem and cortical areas of
mice (Rosenman and Smith 1972; Smith et al. 1972; Bloom et al. 1976; Attila et al.
1987; Etemadzadeh 1993, 1994). Thus, the present results give more evidence that in
mice acute morphine administration increases cerebral NA turnover and release.
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In mice withdrawn from the repeated morphine treatment for 1 day, a clear tolerance to
the NA turnover and release increasing effect of acute morphine was found in all brain
areas studied. At 3-day withdrawal the larger 30 mg/kg morphine challenge dose
slightly accelerated the αMT-induced NA depletion in the area "rest of forebrain +
midbrain", indicating partial loss of tolerance. Furthermore, acute morphine challenge
slightly increased the free MOPEG concentration in all brain areas studied but there
still was a clear tolerance to the acute morphine-induced increase of free MOPEG
concentration in all brain areas. In mice withdrawn for 5 days from the repeated
morphine treatment the acute morphine-induced elevation of the free MOPEG
concentration in the area "rest of forebrain + midbrain" and in the lower brain stem no
longer differed from that of control mice, but in the hypothalamus there still was some
tolerance to the acute morphine-induced elevation of free MOPEG concentration. The
results indicate that mice withdrawn from morphine are tolerant to the cerebral NA
turnover and release increasing effect of acute morphine shortly after the withdrawal,
but the tolerance disappears within a few days even after such a substantial treatment
as was used in the present study. Thus, although withdrawal from morphine has only
minor effects on the basal NA turnover and release in mice, it alters the response of the
cerebral noradrenergic systems to a morphine challenge dose. Furthermore, the results
suggest that there are differences between mice and rats in the effects of chronic
morphine administration on the noradrenergic systems as in rats, in contrast to mice,
the morphine challenge dose does not alter, or may even decrease, cerebral NA
turnover and release during withdrawal from chronic morphine treatment (Roffman et
al. 1977; Attila and Ahtee 1983, 1984a; Ahtee et al. 1989; Attila 1989; Milanes et al.
1993).
6.2.3. Idazoxan pretreatment
1-20 mg/kg of idazoxan has been found to increase NA metabolism and release in
various rat brain areas (Scatton et al. 1983; Curet et al. 1987; Dennis et al. 1987;
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Thomas et al. 1994). Based on preliminary experiments, idazoxan was used in the
present study at doses of 1 and 3 mg/kg and these doses did not alter the locomotor
activity of the NMRI mice used. When given alone to the control mice idazoxan
slightly increased the NA concentration in the area "rest of forebrain + midbrain" and
in the hypothalamus but did not significantly alter the free MOPEG concentration in
any brain area studied. It was found previously that 1 and 5 mg/kg of idazoxan
increase the free MOPEG concentration in the whole brain of C57/Bl mice (Heal et al.
1989), suggesting that the magnitude of the response of idazoxan may slightly vary in
different mouse strains. In combination with morphine idazoxan enhanced the acute
morphine-induced increase of free MOPEG concentration in the area "rest of forebrain
+ midbrain" and in the lower brain stem and decreased the NA concentration in the
lower brain stem. Thus, in the control mice the effect of idazoxan alone on the basal
cerebral NA metabolism was minor. However, inhibition of the negative feedback
mechanism of noradrenergic neurons via α2-adrenoceptors by idazoxan slightly
enhanced the acute morphine-induced increase NA turnover and release.
In contrast to control mice in mice withdrawn from the repeated morphine treatment
for 3 days, idazoxan alone and in combination with morphine clearly enhanced the
cerebral NA turnover. Thus, in the morphine-withdrawn mice idazoxan alone dose-
dependently increased the free MOPEG concentration in the area "rest of forebrain +
midbrain" and in the lower brain stem. However, in the hypothalamus of the morphine-
withdrawn mice, idazoxan did not alter the free MOPEG concentration, suggesting
that the hypothalamic noradrenergic systems during morphine withdrawal function
differently from those of other brain areas. This agrees with the finding of the present
study that in contrast to the other two brain areas studied in the hypothalamus of mice
withdrawn for 1 day from the repeated morphine treatment, NA turnover and release
was not enhanced and tolerance to the effects of acute morphine on NA metabolism
persisted longer in the hypothalamus than in the other two brain areas. In combination
with morphine, idazoxan clearly enhanced the morphine challenge-induced increase of
the free MOPEG concentration in all brain areas of the morphine-withdrawn mice,
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elevating the free MOPEG concentration to about the same level as in corresponding
control mice. Thus, idazoxan pretreatment counteracted the reduction induced by
tolerance towards the acute morphine-induced increase in free MOPEG concentration.
The effect of idazoxan on the cerebral NA release is suggested to be mediated
primarily by presynaptic α2-adrenoceptors on noradrenergic nerve terminals, rather
than by α2-receptors located postsynaptically, somatodendritically or on the terminals
of other neuronal inputs (Dennis et al. 1987; Thomas et al. 1994). Therefore, the
present results suggest that the reduced responsiveness of the cerebral noradrenergic
systems to a morphine challenge, brought about by tolerance, can be overcome by
blocking the presynaptic α2-adrenoceptors by idazoxan. As discussed in section 6.1.3.,
the present findings indicate that although idazoxan altered the striatal DA metabolism
both in the control and morphine-withdrawn mice, 1 mg/kg of idazoxan did not alter
the morphine challenge-induced release of striatal DA and 3 mg/kg of idazoxan did
not potentiate the effects of morphine challenge on striatal DA release in the
morphine-withdrawn mice. However, the morphine-induced release of NA was clearly
enhanced in the morphine-withdrawn mice by idazoxan pretreatment as indicated by
the elevated MOPEG concentration after combined administration of acute morphine
and idazoxan. Thus, idazoxan's effects on striatal DA clearly differ from its effects on
cerebral NA.
Withdrawal from repeated morphine treatment may alter the number or affinity of
cerebral α2-adrenoceptors and thus contribute to the altered response of the morphine
challenge dose and idazoxan during the withdrawal. However, the results of studies on
the binding of the α2-adrenoceptor agonist [
3H]clonidine in various rat brain areas after
chronic morphine treatment and withdrawal vary: a decrease, an increase or no change
in the binding parameters (Hamburg and Tallman 1981; Ulibarri et al. 1987; Vicentini
et al. 1983; Smith et al. 1989). Furthermore, as it has been suggested that the changes
in the number of α2-adrenoceptors do not necessarily correlate with the function of
these receptors after chronic morphine treatment (Smith et al. 1989), the contribution
of the changes in α2-adrenoceptor density or function to the effects of idazoxan
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pretreatment and morphine challenge dose during morphine withdrawal still need to be
elucidated.
Selective α2-adrenoceptor antagonists may induce their effects partially via other
receptors than α2 (section 2.4.). Idazoxan binds to non-adrenoceptor imidazoline I2
binding sites (Hussain et al. 1993; Miralles et al. 1993). However, this may not
contribute to the altered NA release found in the present study since idazoxan labels
imidazoline binding sites in the rat, guinea-pig and human but not in the mouse
cerebral cortex membranes (Hussain et al. 1993). Furthermore, the effects of idazoxan
on cerebral NA or DA turnover and release most probably do not involve its
interaction with opioid receptors, as it has been shown that idazoxan has low affinity
for opioid receptors in vitro (Doxey et al. 1983). Furthermore, the experiments of
Boronat et al. (1998) suggest that the effects of idazoxan on morphine tolerance in rats
do not involve a direct interaction with opioid receptors. On the other hand, idazoxan
is an agonist at cerebral 5-HT1A-autoreceptors and decreases cerebral 5-HT
metabolism in rats at doses higher than 5 mg/kg (Llado et al. 1996). Thus, it cannot
fully be excluded that receptors other than α2-adrenoceptors on noradrenergic nerve
terminals may contribute to the alteration of NA metabolism by idazoxan and may thus
be involved in the mediation of its effects on the behaviour of mice.
6.3. Locomotor activity
6.3.1. Morphine withdrawal
One day withdrawal from the repeated morphine treatment slightly decreased the
locomotor activity of mice. However, after 3- or 5-day withdrawal from the repeated
morphine treatment the locomotor activity was no longer altered. In the experiments of
Oliverio and Castellano (1974) after a 2-day repeated morphine treatment (no
withdrawal) the locomotor activity of mice was not altered. Furthermore, in mice
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withdrawn for 4-8 hours from a 2-day repeated morphine treatment, the locomotor
activity was also not altered (Rethy et al. 1971), but in mice implanted with morphine
pellets the locomotor activity was reduced at 4 days after the implantation (Navarro et
al. 1992). Together these results suggest that the effects of repeated morphine
treatment and withdrawal on mouse spontaneous locomotor activity are modest.
6.3.2. Morphine challenge
In the control mice acute morphine dose-dependently increased the locomotor activity.
In mice withdrawn from the repeated morphine treatment for 1 day the acute morphine
challenge dose did not induce locomotor hyperactivity at all, while in mice withdrawn
for 3 days, the morphine challenge increased the locomotor activity to about the same
extent as in the control mice. After 5-day withdrawal the motility of mice was
increased by the morphine challenge dose clearly more than in the control mice. Thus,
the morphine-withdrawn mice were tolerant to the locomotor activity increasing effect
of acute morphine at 1-day withdrawal while a clear sensitization of the acute
morphine-induced locomotor hyperactivity could be seen at 5-day withdrawal. These
results are in agreement with previous studies which indicate that in most mouse
strains the predominant behavioural effect of acute morphine is locomotor
hyperactivity (Table 2-1) to which tolerance develops during chronic morphine
treatment (Rethy et al. 1971; Oliverio and Castellano 1974; Ülkü et al. 1980; Ahtee et
al. 1987). However, there is evidence that after sufficiently long chronic morphine
treatment and withdrawal (Fernandes et al. 1977; Gwynn and Domino 1984) or after
intermittent morphine administration (Kuribara 1995, 1996, 1997) the tolerance
disappears and acute morphine increases the locomotor activity to a greater extent than
in control mice. The present results confirm this suggestion and show that like rats
(Fog 1970; Babbini and Davis 1972; Kalivas and Duffy 1987; Vezina et al. 1987;
Spanagel and Shippenberg 1993) mice are clearly sensitized to the acute morphine-
induced locomotor hyperactivity after long enough repeated morphine treatment and
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withdrawal.
6.3.3. Idazoxan pretreatment
In the control mice, idazoxan alone did not alter the locomotor activity. This agrees
with studies in which similar, relatively small doses of idazoxan were used
(Chojnacka-Wojcik 1992; Jackson et al. 1992). Furthermore, in the control mice
idazoxan pretreatment did not alter the acute morphine-induced locomotor
hyperactivity. However, in mice withdrawn for 3 days from the repeated morphine
treatment in which acute morphine increased the locomotor activity similarly as in
control mice, idazoxan pretreatment clearly potentiated the morphine challenge-
induced locomotor hyperactivity. As discussed in section 6.3.2., sensitization to the
acute morphine-induced locomotor hyperactivity was found first at 5-day withdrawal.
Thus, modulating the function of the cerebral noradrenergic systems by idazoxan
reveals the morphine-induced locomotor sensitization already at 3-day withdrawal,
whereas in non-idazoxan pretreated mice the sensitization is expressed first at 5-day
withdrawal.
6.4. Striatal dopamine and cerebral noradrenaline as determinants of locomotor
sensitization to morphine in mice 
The cerebral dopaminergic neurons are considered important in the mediation of the
morphine-induced locomotor activity in rats (Joyce and Iversen 1979; Havemann and
Kuschinsky 1982; Kalivas and Duffy 1987; Kalivas and Stewart 1991; Spanagel et al.
1991). Also in mice the role of cerebral dopaminergic systems is well established in
the morphine-induced locomotor activity (Carrol and Sharp 1972; VanderWende et al.
1975; Racagni et al. 1979; Reggiani et al. 1980; Wood and Richard 1982, Longoni et
al. 1987; Saito 1990; Navarro et al. 1992; Funada et al. 1993b, 1994). However, in
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mice the cerebral noradrenergic systems also have a role in the morphine-induced
changes of locomotor activity (Estler 1973, Kempf et al. 1976, Ayhan 1978; Filibeck
et al. 1980; Havemann and Kuschinsky 1982; Marona-Lewicka and Vetulani 1989;
Michaluk et al. 1991).
In the present study the morphine challenge dose increased the striatal DA turnover
and release at 1 day withdrawal less than in control mice, while mice were sensitized
to morphine about similarly at 3- and 5-day withdrawal from the repeated morphine
treatment. Locomotor sensitization to morphine was found at 5-day withdrawal, but
not at 3-day withdrawal. At 3-day withdrawal but no longer at 5-day withdrawal the
mice were tolerant to the acute morphine-induced increase in the cerebral free
MOPEG concentration. However, in mice withdrawn from morphine for 3 days and
pretreated with idazoxan, acute morphine induced locomotor sensitization. Moreover,
at 3-day withdrawal the morphine challenge dose elevated the free MOPEG
concentration of the idazoxan-pretreated mice to the same degree as in the control
mice, thus counteracting the effect of tolerance on cerebral NA metabolism. Thus, on
the basis of the present results it is possible that the morphine-induced sensitization of
locomotor activity cannot be expressed in morphine-withdrawn mice until the
responsiveness of the cerebral noradrenergic systems to a morphine challenge is
regained, either after sufficiently long withdrawal period or by modulating the function
of the cerebral noradrenergic systems by idazoxan.
It is to be noted that in the control mice, idazoxan pretreatment did not alter the
morphine-induced locomotor hyperactivity. This might be due to the findings that,
unlike in the morphine-withdrawn mice, in the control mice the doses of idazoxan used
did not stimulate the cerebral noradrenergic systems and potentiated morphine's effects
on these systems only to a minor degree. Although idazoxan pretreatment slightly
altered the striatal DA metabolism both in the control and morphine-withdrawn mice,
it did not potentiate the morphine-induced increase in striatal DA turnover and release
in mice withdrawn from the repeated morphine treatment.
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The temporal coupling between morphine-induced changes in locomotor activity and
cerebral NA and DA metabolism suggests that the morphine-induced sensitization of
locomotor activity may be expressed in mice only when they are sensitized to the
striatal DA turnover and release increasing effect of acute morphine and when acute
morphine simultaneously increases cerebral NA turnover and release to the same
extent as in naive mice. As the present results show that the morphine-induced changes
in striatal DA metabolism are about similar in mice as in rats it is suggested that, as in
rats, the sensitization of morphine-induced hyperactivity in morphine-withdrawn mice
is brought about by hyperactive dopaminergic systems. However, in the withdrawn
mice this effect can be masked by tolerance of their cerebral noradrenergic systems.
Only when the noradrenergic neuronal activity is restored, morphine-withdrawn mice,
like rats, react to morphine challenge with locomotor hyperactivity. Furthermore, these
findings support the view that in mice both the cerebral noradrenergic as well as
dopaminergic systems are major determinants of locomotor response to morphine. To
elucidate the more specific cerebral mechanisms of the locomotor sensitization to
morphine, strains of mice genetically engineered to have overexpression or deficiency
regarding certain α-adrenoceptor or DA receptor subtypes could be utilized. However,
α1-adrenoceptor agonists or antagonists could also be used.
The morphine-induced behavioural sensitization has been implicated in its reinforcing
effects (Shippenberg et al. 1996). As there is evidence that in rats the activation of
cerebral noradrenergic transmission may be involved in the control of locomotor
activity (Ögren et al. 1983; Dickinson et al. 1988; Darracq et al. 1998; Salmi et al.
1998), it is possible that the cerebral noradrenergic mechanisms might be involved in
the sensitization of the locomotor response and related phenomena after repeated
morphine treatment not only in mice but in other species as well.
87
7. CONCLUSIONS
                            
One-day but not 3- or 5-day withdrawal from the repeated morphine treatment
decreased striatal DA turnover and release, indicating that the activity of striatal
dopaminergic neurons is attenuated in mice shortly after the withdrawal from
morphine. At 1-day withdrawal, the acute morphine partially counteracted the
withdrawal-induced retardation of striatal DA depletion, and increased the striatal
DOPAC and HVA concentrations less than in control mice. This indicates reduced
response to the striatal DA turnover and release enhancing effect of acute morphine.
However, at 3- and 5-day withdrawal the acute morphine-induced increase in striatal
DA turnover and release was enhanced, indicating that after repeated morphine
treatment and sufficiently long withdrawal, mice are sensitized to the acute morphine-
induced increase of striatal DA turnover and release. The down-regulation of striatal
D2-receptors found at 3-day withdrawal may contribute to the sensitization.
In mice withdrawn for 1 day from the repeated morphine treatment, the αMT-induced
NA depletion was retarded in the forebrain but the free MOPEG concentration was
elevated in all brain areas studied. After longer withdrawal periods, NA turnover and
release was not altered in any brain area. In mice withdrawn from the repeated
morphine treatment for 1 or 3 days, the NA turnover and release increasing effect of
acute morphine was reduced in all brain areas studied but at 5-day withdrawal the
reduction was found only in the hypothalamus. These results suggest that in mice
withdrawal from repeated morphine treatment may induce dual effects on the cerebral
NA turnover and release but the effects are modest and are observed only shortly after
the withdrawal. Furthermore, there is a clear tolerance to the cerebral NA turnover and
release increasing effect of acute morphine shortly after the withdrawal but it
disappears within a few days.
At 1-day withdrawal, mice were tolerant to the acute morphine-induced locomotor
hyperactivity, at 3-day withdrawal acute morphine increased their locomotor activity
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similarly as in control mice, and at 5-day withdrawal acute morphine increased the
locomotor activity clearly more than in control mice. This suggests that after repeated
morphine treatment and sufficiently long withdrawal mice are sensitized to the acute
morphine-induced locomotor hyperactivity.
In the control mice and in mice withdrawn from the repeated morphine treatment for 3
days, idazoxan slightly altered the acute morphine-induced increase in striatal DA
metabolism. In the control mice, idazoxan alone had no effect on the cerebral free
MOPEG concentration, and pretreatment with idazoxan only slightly enhanced the
acute morphine-induced increase in cerebral free MOPEG concentration. However, the
acute morphine-induced increase in the cerebral free MOPEG concentration was
clearly enhanced by idazoxan in the morphine-withdrawn mice. In the control mice,
idazoxan alone did not alter the locomotor activity or acute morphine's effect on it, but
in mice withdrawn for 3 days from morphine idazoxan pretreatment clearly potentiated
the acute morphine-induced locomotor hyperactivity. Thus, as idazoxan pretreatment
in the morphine-withdrawn mice did not potentiate the effects of the morphine
challenge dose on striatal DA release, as it abolished the tolerance towards the acute
morphine-induced increase in cerebral NA release and as it clearly potentiated the
acute morphine-induced locomotor hyperactivity, it is possible that the morphine-
induced sensitization of locomotor activity cannot be expressed in the morphine-
withdrawn mice until the responsiveness of the cerebral noradrenergic systems to a
morphine challenge is regained, either after sufficiently long withdrawal period or by
modulating the function of the cerebral noradrenergic systems. The temporal coupling
of morphine-induced changes in striatal DA and cerebral NA metabolism and
locomotor activity suggests that the morphine-induced sensitization of locomotor
activity is expressed in mice only when they are sensitized to the striatal DA turnover
and release increasing effect of acute morphine and when acute morphine increases
cerebral NA turnover and release to the same extent as in naive mice. The sensitization
of morphine-induced hyperactivity in morphine-withdrawn mice is most probably
brought about by hyperactive dopaminergic systems. However, in the withdrawn mice
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this effect can be masked by tolerance of their cerebral noradrenergic systems; only
when noradrenergic tone is restored, the morphine challenge induces locomotor
hyperactivity. Thus, the results of the present study emphasize the role of the striatal
dopaminergic, as well as that of the cerebral noradrenergic systems, in the expression
of behavioural sensitization in mice.
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